SSYS Stratasys Ltd

---

---

---

---

---

---

---

---

---

Note 1. Business Description and Basis of Presentation

 Stratasys Ltd. (collectively with its subsidiaries, the “Company” or “Stratasys”) is a global leader in connected, polymer-based 3D printing solutions, across the entire manufacturing value chain. The Company leverages its competitive advantages, which include a broad set of best-in-class 3D printing platforms, software, a materials and technology partner ecosystem, innovative leadership, and global GTM infrastructure, in order to position itself to capture share in a significant and growing global marketplace, with a focus on manufacturing, which the Company views as having the largest and fastest growing total addressable market. The Company’s approximately 2,600 granted and pending additive technology patents to date have been used to create models, prototypes, manufacturing tools, and production parts for a multitude of industries including aerospace, automotive, transportation, healthcare, consumer products, dental, medical, fashion and education. Stratasys’ products and comprehensive solutions improve product quality, development time, cost, time-to-market and patient care. The Company’s 3D ecosystem of solutions and expertise includes 3D printers, materials, software, expert services, and on-demand parts production.

The condensed consolidated interim financial information herein is unaudited; however, such information reflects all adjustments (consisting of normal, recurring adjustments), which are, in the opinion of management, necessary for a fair statement of results for the interim period. The condensed consolidated interim financial statements include the accounts of Stratasys Ltd. and its subsidiaries. All intercompany accounts and transactions, including profits from intercompany sales not yet realized outside the Company, have been eliminated in consolidation.

The Company’s financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), which require the Company to make estimates based on assumptions about current and, for some estimates, future economic and market conditions which affect reported amounts and related disclosures in its financial statements. Although the Company’s current estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from the Company’s expectations, which could materially affect its results of operations and financial position.

In particular, a number of estimates have been and will continue to be affected by global events and other longer-term macroeconomic conditions, most prominently, the extent and speed at which inflation subsides, whether and when interest rates are reduced by central banks, whether and when tight credit conditions are loosened, whether capital markets continue to rise and whether global supply chains remain open. As a result, the accounting estimates and assumptions may change over time. Such changes could have an additional impact on the Company’s long-lived asset, goodwill and intangible asset valuations; and the allowance for expected credit losses. These consolidated financial statements reflect the financial statement effects based upon management’s estimates and assumptions utilizing the most currently available information. 

In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these financial statements, the war in Israel is ongoing and continues to evolve. One of the Company’s global headquarters and one of its manufacturing facilities are located in Israel. As of the publication date of these financial statements, the Company's activities in Israel remain largely unaffected by the war. During the six months ended June 30, 2024, the impact of the war on the Company’s results of operations and financial condition was limited, but such impact may change, and could be significant, as a result of the continuation, escalation or expansion of the war. The Company continues to maintain business continuity plans backed by its inventory levels located outside of Israel.

The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain financial information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. The reader is referred to the Company's audited consolidated financial statements and notes thereto for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 11, 2024 as part of the Company’s Annual Report on Form 20-F for such year.

Note 2. New Accounting Pronouncements

    Recently issued accounting pronouncements, not yet adopted

In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements related disclosures.

In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

---

Note 3. Certain Transactions

  Covestro acquisition

On April 3, 2023 (the “Covestro transaction date”), the Company completed the acquisition of the additive manufacturing materials business of Covestro AG. Covestro’s additive manufacturing business is expected to give the Company the ability to accelerate innovative developments in 3D printing materials and to thereby further grow adoption of its newest technologies. Also, the Company acquired an IP portfolio comprised of hundreds of patents and pending patents, including all of the SOMOS™ portfolio.

The Covestro transaction is reflected in accordance with ASC Topic 805, “Business Combinations”. The assets acquisition transaction meets the definition of a business and was accounted for as a “Business Combinations” transaction, using the acquisition method of accounting with the Company as the acquirer. The following table summarizes the fair value of the consideration transferred to Covestro AG for the Covestro transaction:

			U.S. $ in thousands
Cash payments			$	53,815
Issuance of ordinary shares to Covestro stockholders			5,202
Contingent consideration at estimated fair value			659
Other liability			868
Total consideration			$	60,544

The fair value of the ordinary shares issued was determined based on the closing market price of the Company's ordinary shares on the Covestro transaction date.

In accordance with ASC Topic 805, the estimated contingent consideration as of the Covestro transaction date was included in the purchase price. The total contingent payments could amount to a maximum aggregate amount of up to €37 million. The payment will be settled through the issuance of ordinary shares. The estimated fair value of the contingent consideration is based on management’s assessment of whether, and at what level, the financial metrics will be achieved, and the present value factors associated with the timing of the payments. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. Changes in the fair value of contingent consideration will be recorded in operating expenses. Refer to Note 9.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the Covestro transaction date. The estimated fair values are based on the information that was available as of April 3, 2023. The allocation of the purchase price to assets acquired and liabilities assumed is as follows:

			Allocation of Purchase Price
			U.S. $ in thousands
Inventory			$	10,342
Fixed assets			7,064
Intangible assets			21,929
Other liabilities			(605)
Total identifiable net assets			38,730
Goodwill			21,814
Total consideration			$	60,544

The allocation of the PPA to net assets acquired and liabilities assumed resulted in the recognition of intangible assets related to developed technology, customer relationship, and trade name. These intangible assets have a useful life of 7 to 10 years. The fair value estimate of the customer relationship was determined using a variation of the income approach known as the “Multi-Period Excess Earnings Approach”. This valuation technique estimates the fair value of an asset based on market participants’ expectations of the cash flows the asset would generate over its remaining useful life. The net cash flows were discounted to present value. The fair value estimate of the developed technology and trade name, were estimated using the "Relief from royalty" method. This valuation technique estimates the fair value of the asset based on the hypothetical royalty payment that a licensee would be required to pay in exchange for use of the asset. Goodwill was recorded as the residual amount by which the purchase price exceeded the provisional fair value of the net assets acquired and is expected to be fully deductible for tax purposes. Goodwill consists primarily of expected synergies of combining operations, the acquired workforce, and growth opportunities, none of which qualify as separately identifiable intangible assets.

Pro forma information giving effect to the acquisition has not been provided, as the results would not be material.

During 2023, the Company completed several transactions, including acquisitions of an entity and additional assets, for a total consideration of $22 million.

MakerBot and Ultimaker transaction ("Ultimaker")

On August 31, 2022, Stratasys completed the merger of MakerBot (previously, a wholly-owned subsidiary) with Ultimaker, which together formed a new entity under the name Ultimaker.

The Company accounts for its investment in the combined company Ultimaker according to the equity method in accordance with ASC Topic 323, as it has retained the ability to exercise significant influence but does not control the new entity. The Company recognized an equity method investment in a total amount of $105.6 million comprised of the assumed fair value of the MakerBot shares and additional amount invested in cash by the Company, representing a share of 46.5% in the new entity.

During 2023, Ultimaker encountered difficulties in its business partially as a result of tighter competition and global market conditions. As a result, senior management at Ultimaker was replaced and the new management implemented a restructuring plan and additional steps to reduce cost and improve profitability. The Company considered such events as indicators of potential impairment and accordingly performed an impairment analysis for the investment in Ultimaker. Based on such valuation, the fair value of the investment was estimated below its carrying amount and such reduction in fair value was determined to be other than temporary. Accordingly the Company recorded an impairment charge in an amount of $13.9 million, which was recorded in share in losses of associated companies in the consolidated statements of operations and comprehensive loss. Management’s cash flow projections for the fair value of the investment in Ultimaker include significant judgments and assumptions relating to the cash flow projections, future growth and future profitability. Actual results could differ from those estimates, and such differences could be material and may result in other than temporary reduction in fair value, which could lead to additional impairments in the carrying value of the Ultimaker investment.

On March 22, 2024, Ultimaker's shareholders agreed to provide it with additional funding of $8.0 million in cash, out of which $4.5 million was funded by the Company during the six months ended June 30, 2024.

As of June 30, 2024 and December 31, 2023 the Company's equity investment in Ultimaker amounted to $72.2 million and $67.8 million, respectively, which represents the Company's investment in Ultimaker, net of the Company's share in Ultimaker's net losses for the respective periods in amounts of $0.1 million and $32.4 million, respectively.

Other long-term investments

In addition to the investment in Ultimaker, other investments included under Long-term investments represent investments in non-marketable equity securities and convertible notes of several companies without readily determinable fair value in which the Company does not have a controlling interest or significant influence. During the six months ended June 30, 2024 and during 2023, the Company invested a total of $5.4 million and $11.5 million, respectively, in non-marketable equity securities and convertible notes of several companies.

---

Note 4. Revenues

Disaggregation of Revenues

The following table presents the Company’s revenues disaggregated by geographical region (based on the Company's customers' locations) and revenue type for the three and six months ended June 30, 2024

and 2023:

			Three Months Ended June 30,												Six Months Ended June 30,
			2024						2023						2024						2023
			(U.S. $ in thousands)												(U.S. $ in thousands)
Americas
Systems			$	14,054					$	28,975					$	32,047					$	50,161
Consumables			36,182						33,757						71,724						66,329
Service			33,252						39,463						66,525						75,785
Total Americas			83,488						102,195						170,296						192,275
EMEA
Systems			9,800						12,054						19,523						23,456
Consumables			19,945						17,910						41,115						36,821
Service			7,308						6,920						14,888						14,487
Total EMEA			37,053						36,884						75,526						74,764
Asia Pacific
Systems			5,125						7,284						10,294						15,148
Consumables			8,488						9,132						18,087						18,168
Service			3,887						4,256						7,888						8,773
Total Asia Pacific			17,500						20,672						36,269						42,089
Total Revenues			$	138,041					$	159,751					$	282,091					$	309,128

The following table presents the Company’s revenues disaggregated based on the timing of revenue recognition (at a specific point in time or over the course of time) for the three and six months ended June 30, 2024 and 2023:

			Three Months Ended June 30,												six months ended June 30, 2024
			2024						2023						2024						2023
			(U.S. $ in thousands)												(U.S. $ in thousands)
Revenues recognized in point in time from:
Products			$	93,594					$	109,112					$	192,790					$	210,083
Services			12,847						14,156						26,619						27,847
Total revenues recognized in point in time			106,441						123,268						219,409						237,930
Revenues recognized over time from:
Services			31,600						36,483						62,682						71,198
Total revenues recognized over time			31,600						36,483						62,682						71,198
Total Revenues			$	138,041					$	159,751					$	282,091					$	309,128

Contract Assets and Contract Liabilities

Contract assets are recorded when the Company's right to consideration is conditioned on constraints other than the passage of time. The Company had no material contract assets as of June 30, 2024 and December 31, 2023.

Contract liabilities include advance payments and billings in excess of revenue recognized, which are primarily related to advanced billings for service type warranty. Contract liabilities are presented under deferred revenue. The Company's deferred revenue as of June 30, 2024 and December 31, 2023 was as follows:

			June 30,			December 31,
			2024			2023
			U.S. $ in thousands
Deferred revenue *			$	69,794		$	76,265

*Includes $18.9 million and $23.7 million under long-term deferred revenue in the Company's consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively.

Revenue recognized in 2024 that was included in deferred revenue balance as of December 31, 2023 was $14.5 million and $33.1 million  for the three and six months ended June 30, 2024, respectively.

Remaining Performance Obligations

Remaining Performance Obligations (“RPO“) represent contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. As of June 30, 2024, the total RPO amounted to $98.3 million. The Company expects to recognize $68.0 million of this RPO during the next 12 months, $14.7 million over the subsequent 12 months and the remaining $15.6 million thereafter.

Incremental Costs of Obtaining a Contract

---

Note 5. Inventories

Inventories consisted of the following:

						June 30, 2024						December 31, 2023
						U.S. $ in thousands
Finished goods						$	95,670					$	86,908
Work-in-process						9,870						9,871
Raw materials						90,965						96,197
						$	196,505					$	192,976

Note 6. Goodwill and Other Intangible Assets

 Goodwill

Changes in the carrying amount of the Company’s goodwill during the six months ended June 30, 2024 were as follows:

						U.S. $ in thousands
Goodwill as of January 1, 2024						$	100,051
Foreign currency translation adjustments						(877)
Goodwill as of June 30, 2024						$	99,174

During the fourth quarter of 2023, the Company performed its annual impairment test for goodwill impairment. The Company performed a quantitative assessment for goodwill impairment for its Stratasys-Core reporting unit and concluded that the fair value of Stratasys-Core reporting unit exceeded its carrying amount by approximately 34%, with a carrying amount of goodwill assigned to this reporting unit in an amount of $100.0 million. When evaluating the fair value of Stratasys-Core reporting unit under the income approach, the Company used a discounted cash flow model which utilized Level 3 measures that represent unobservable inputs. Key assumptions used to determine the estimated fair value include: (a) internal cash flows forecasts for 4 years following the assessment date, including expected revenue growth, costs to produce, operating profit margins and estimated capital needs; (b) an estimated terminal value using a terminal year long- term future growth determined based on the growth prospects of the reporting unit; and (c) a discount rate which reflects the weighted average cost of capital adjusted for the relevant risk associated with the Stratasys-Core reporting unit operations and the uncertainty inherent in the Company's internally developed forecasts.

In order to assess the reasonableness of its cash flow projections used for its goodwill impairment analysis, the Company compared the aggregate fair value of its reporting units to its market capitalization and calculated the implied control premium. The Company believes that its fair value assessment is reasonably supported by its calculated market capitalization.

Actual results may differ from those assumed in the Company's valuation method. It is reasonably possible that the Company's assumptions described above could change in future periods. If any of these were to vary materially from the Company's plans, it may record impairment of goodwill allocated to this reporting unit in the future.

Based on the Company’s assessment as of December 31, 2023, no goodwill was determined to be impaired.

---

During the second quarter of 2024, the Company performed an analysis of the impact of recent events, including business and industry specific considerations, on the fair value of Stratasys-Core reporting unit. As part of this analysis the Company considered the changes in market capitalization and the sensitivity of estimates and assumptions used in the last annual impairment test as well as potential impacts of macro-economic pressure. The Company also analyzed the aggregate fair value of its reporting units compared to its market capitalization as part of its goodwill impairment test, in order to assess the reasonableness of the results of its cash flow projections used for its goodwill impairment analysis. The Company noted its market capitalization was below management’s assessment of the aggregate fair value of its reporting units. However, as of June 30, 2024, the Company’s market capitalization plus a reasonable control premium exceeded its book value.

While management believes the goodwill of the reporting unit is currently not impaired, there can be no assurances that goodwill will not be impaired in future periods. The Company will continue to monitor the fair value of its Stratasys-Core reporting unit to determine whether events and changes in circumstances such as further deterioration in the business climate or operating results, significant decline in the Company's share price, changes in management’s business strategy or downward changes of the Company's cash flows projections, warrant further interim impairment testing.

Other Intangible Assets

Other intangible assets consisted of the following:

						June 30, 2024									December 31, 2023
						Carrying Amount, net of Impairment			Accumulated Amortization			Net book value			Carrying Amount, net of Impairment			Accumulated Amortization			Net book value
						U.S. $ in thousands
Developed technology						$	403,035		$	(309,542)		$	93,493		$	403,180		$	(300,780)		$	102,400
Patents						20,975			(11,041)			9,934			19,396			(10,246)			9,150
Trademarks and trade names						22,161			(16,940)			5,221			22,286			(15,936)			6,350
Customer relationships						102,634			(94,821)			7,813			102,520			(92,639)			9,881
Capitalized software development costs						3,236			(3,236)			—			4,367			(4,367)			—
						$	552,041		$	(435,580)		$	116,461		$	551,749		$	(423,968)		$	127,781

---

Amortization expenses relating to intangible assets for the three-month periods ended June 30, 2024 and 2023 were approximately $5.7 million and $7.1 million, respectively. Amortization expenses relating to intangible assets for the six-month periods ended June 30, 2024 and 2023 were approximately $12.6 million and $13.3 million, respectively.

As of June 30, 2024, the estimated amortization expenses relating to intangible assets for each of the following future periods were as follows:

						Estimated amortization expenses
						(U.S. $ in thousands)
Remaining 6 months of 2024						$	11,245
2025						21,336
2026						21,247
2027						20,320
2028						16,290
2029 and thereafter						26,023
Total						$	116,461

Note 7. Net Loss Per Share

The following table presents the numerator and denominator of the basic and diluted net loss per share computations for the three and six months ended June 30, 2024 and 2023:

						Three Months Ended June 30,												Six Months Ended June 30,
						2024						2023						2024						2023
						In thousands, except per share amounts												In thousands, except per share amounts
Numerator:
Net loss for basic and diluted net loss per share						$	(25,743)					$	(38,615)					$	(51,726)					$	(60,839)
Denominator:
Weighted average shares - for basic and diluted net loss per share						70,746						68,648						70,367						68,107
Net loss per share
Basic and diluted						$	(0.36)					$	(0.56)					$	(0.74)					$	(0.89)

 The computation of diluted net loss per share excluded share awards of 5.5 million shares and 3.0 million million shares for the three months ended June 30, 2024 and 2023 respectively, because the inclusion of those shares would have had an anti-dilutive effect on the diluted net loss per share. 

The computation of diluted net loss per share excluded share awards of 3.9 million shares and 3.3 million shares for the six months ended June 30, 2024 and 2023 respectively, because the inclusion of those shares would have had an anti-dilutive effect on the diluted net loss per share.

---

The Company had income tax expenses of $0.8 million for the three-month period ended June 30, 2024, compared to income tax expenses of $0.7 million for the three-month period ended June 30, 2023. The Company had income tax expenses of $1.5 million for the six-month period ended June 30, 2024, compared to income tax expenses of $4.5 million for the six-month period ended June 30, 2023. The Company’s effective tax rate as of June 30, 2024, was primarily impacted by the geographic mix of its earnings and losses, movements in its valuation allowance and changes in its uncertain tax positions.

The following table summarizes the Company’s financial assets and liabilities that are carried at fair value on a recurring basis, in its consolidated balance sheets:

						June 30, 2024																		December 31, 2023
						Level 1						Level 2						Level 3						Level 1						Level 2						Level 3
						(U.S. $ in thousands)
Assets:
Foreign exchange forward contracts not designated as hedging instruments						$	—					$	82					$	—					$	—					$	164					$	—
Foreign exchange forward contracts designated as hedging instruments						—						1,485						—						—						2,087						—
Convertible notes						—						—						8,786						—						—						7,018
Marketable securities						828																		1,994						—						—
Liabilities:
Foreign exchange forward contracts not designated as hedging instruments						—						(31)						—						—						(51)						—
Foreign exchange forward contracts designated as hedging instruments						—						(47)						—						—						(657)						—
Contingent consideration*						—						—						(18,371)						—						—						(18,603)
						$	828					$	1,489					$	(9,585)					$	1,994					$	1,543					$	(11,585)

*Includes $6.5 million and $6.7 million under accrued expenses and other current liabilities in the Company's consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively.

The Company's foreign exchange forward contracts are classified as Level 2, as they are not actively traded and are valued using pricing models that use observable market inputs, including interest rate curves and both forward and spot prices for currencies (Level 2 inputs).

Contingent consideration represents liabilities recorded at fair value in connection with acquisitions, and thus represents a Level 3 measurement within the fair value hierarchy (refer to Note 3).

---

Note 10. Derivative instruments and hedging activities

Since the Company conducts its operations globally, it is exposed to global market risks and to the risk that its earnings, cash flows and equity could be adversely impacted by fluctuations in foreign currency exchange rates. The Company enters into transactions involving foreign currency exchange derivative financial instruments. The Company manages its foreign currency exposures on a consolidated basis, which allows the Company to net exposures and take advantage of any natural hedging. The transactions are designed to manage the Company’s net exposure to foreign currency exchange rates and to reduce the volatility of earnings and cash flows associated with changes in foreign currency exchange rates. The Company does not enter into derivative transactions for trading purposes.

The Company is primarily exposed to foreign exchange risk with respect to recognized assets and liabilities and forecasted transactions denominated in the New Israeli Shekel (“NIS”), Euro, British Pound, Korean Won, Chinese Yuan and the Japanese Yen. The gains and losses on the hedging instruments partially offset losses and gains on the hedged items. Financial markets and currency volatility may limit the Company’s ability to hedge these exposures. These contracts mature through December 2024.

The following table summarizes the consolidated balance sheets classification and fair values of the Company’s derivative instruments:

									Fair Value												Notional Amount
			Balance sheet location						June 30, 2024						December 31, 2023						June 30, 2024						December 31, 2023
									U.S. $ in thousands
Assets derivatives -Foreign exchange contracts, not designated as hedging instruments			Other current assets						$	82					$	164					$	35,581					$	82,873
Assets derivatives -Foreign exchange contracts, designated as cash flow hedge			Other current assets						1,485						2,087						54,152						51,830
Liability derivatives -Foreign exchange contracts, not designated as hedging instruments			Accrued expenses and other current liabilities						(31)						(51)						47,237						21,168
Liability derivatives -Foreign exchange contracts, designated as cash flow hedge			Accrued expenses and other current liabilities						(47)						(657)						13,066						74,054
									$	1,489					$	1,543					$	150,036					$	229,925

Foreign exchange contracts not designated as hedging instruments

As of June 30, 2024, the notional amounts of the Company’s outstanding exchange forward contracts, not designated as hedging instruments, were $82.8 million, and were used to reduce foreign currency exposures of the Euro, New Israeli Shekel (the "NIS"), British Pound, Japanese Yen, Korean Won and Chinese Yuan. With respect to such derivatives, a gain of $0.5 million and a gain of $1.6 million were recognized under financial expenses, net for the three-month periods ended June 30, 2024 and 2023, respectively and a gain of $1.8 million and a gain of $1.2 million million were recognized under financial expenses, net for the six-month periods ended June 30, 2024 and 2023, respectively. Such gains partially offset the revaluation losses of the balance sheet items which are also recognized under financial income (expenses), net.

---

Cash Flow Hedging - Hedges of Forecasted Foreign Currency Payroll and other operating expenses

As of June 30, 2024, the Company had in effect foreign exchange forward contracts, designated as cash flow hedges for accounting purposes, for the conversion of $27.3 million into NIS. The Company uses short-term cash flow hedge contracts to reduce its exposure to variability in expected future cash flows resulting mainly from payroll costs denominated in New Israeli Shekels. The changes in fair value of those contracts are included in the Company’s accumulated other comprehensive loss.

Cash Flow Hedging - Hedges of Forecasted Foreign Currency Revenue

The Company transacts business in U.S. Dollars and in various other currencies. The Company may use foreign exchange or forward contracts to hedge certain cash flow exposures resulting from changes in these foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities of up to twelve months. The Company enters into these foreign exchange contracts to hedge a portion of its forecasted foreign currency denominated revenue in the normal course of business, and accordingly, they are not speculative in nature.

As of June 30, 2024, the Company had in effect foreign exchange forward contracts, designated as cash flow hedges for accounting purposes, for the conversion of €36.0 million into dollars.

Note 11. Equity

a. Stock-based compensation plans

Stock-based compensation expenses for equity-classified stock options, restricted share units (“RSUs”) and performance-based restricted share units (”PSUs”) were allocated as follows:

						Three Months Ended June 30,												Six Months Ended June 30,
						2024						2023						2024						2023
						U.S $ in thousands												U.S $ in thousands
Cost of revenues						$	1,010					$	999					$	1,962					$	1,931
Research and development, net						2,120						1,867						4,251						3,956
Selling, general and administrative						4,216						5,156						9,782						10,376
Total stock-based compensation expenses						$	7,346					$	8,022					$	15,995					$	16,263

A summary of the Company’s stock option activity for the six months ended June 30, 2024 is as follows:

						Number of Options						Weighted Average Exercise Price
Options outstanding as of January 1, 2024						1,360,652						20.67
Granted						—						—
Exercised						(12,413)						12.30
Forfeited						(54,569)						24.30
Options outstanding as of June 30, 2024						1,293,670						20.60
Options exercisable as of June 30, 2024						1,014,148						21.80

As of June 30, 2024, the unrecognized compensation cost of $0.3 million related to all unvested, equity-classified stock options is expected to be recognized as an expense over a weighted-average period of 1.56 years.

---

A summary of the Company’s RSUs and PSUs activity for the six months ended June 30, 2024 is as follows:

						Number of RSUs and PSUs						Weighted Average Grant Date Fair Value
Unvested as of January 1, 2024						3,842,232						17.95
Granted						1,867,931						11.77
Vested						(1,020,493)						19.12
Forfeited						(213,697)						19.14
Unvested as of June 30, 2024						4,475,973						18.83

The fair value of RSUs and PSUs is determined based on the quoted price of the Company’s ordinary shares on the date of the grant.

As of June 30, 2024, the unrecognized compensation cost of $55.7 million related to all unvested, equity-classified RSUs and PSUs is expected to be recognized as expense over a weighted-average period of 2.79 years.

b. Accumulated other comprehensive loss

The following tables present the changes in the components of accumulated other comprehensive income (loss), net of taxes, for the six months ended June 30, 2024 and 2023, respectively:

			Six Months Ended June 30, 2024
			Net Unrealized Gain (Loss) on Cash Flow Hedges						Foreign Currency Translation Adjustments						Total
			U.S. $ in thousands
Balance as of January 1, 2024			$	1,790					$	(8,869)					$	(7,079)
Other comprehensive income (loss) before reclassifications			1,459						(2,210)						(751)
Amounts reclassified from accumulated other comprehensive loss			(1,303)						—						(1,303)
Other comprehensive loss			156						(2,210)						(2,054)
Balance as of June 30, 2024			$	1,946					$	(11,079)					$	(9,133)

			Six Months Ended June 30, 2023
			Net Unrealized Gain (Loss) on Cash Flow Hedges						Foreign Currency Translation Adjustments						Total
			U.S. $ in thousands
Balance as of January 1, 2023			$	(299)					$	(12,519)					$	(12,818)
Other comprehensive income before reclassifications			(2,708)						1,834						(874)
Amounts reclassified from accumulated other comprehensive loss			1,021						—						1,021
Other comprehensive income			(1,687)						1,834						147
Balance as of June 30, 2023			$	(1,986)					$	(10,685)					$	(12,671)

---

Note 12. Contingencies

Legal proceedings

Litigation with Nano Dimension regarding Stratasys’ Rights Plan and Nano Dimension’s tender offer

On April 25, 2023, the Company was named as a defendant in an action filed by Nano in the Tel-Aviv District Court in which Nano sought declaratory relief declaring that Stratasys’ shareholder rights plan is both illegal and void, and also requested a court order enjoining the Company and its directors from intervening with, or hindering in any way, a tender offer that Nano at the time intended to launch to acquire Stratasys ordinary shares.

On June 8, 2023, in its statement of defense, the Company rejected all of Nano’s claims, stating, among other things, that there was a substantial change of circumstance since Nano’s action was filed due to Stratasys’ entry into the Desktop Metal Merger Agreement on May 25, 2023 and the launch of Nano’s tender offer on May 25, 2023. The Company argued that its rights plan is legal under Israeli law, and that due to the many flaws and unlawful conditions of Nano’s tender offer and Nano’s conduct and circumstances, The Company’s board was obligated to get involved and protect the Company and its shareholders. The Company also submitted a counterclaim to the court, seeking an order restraining Nano from completing its tender offer until certain conditions were to be fulfilled.

On July 18, 2023, in the context of an interim procedural decision, the Israeli court took the opportunity to express its preliminary view on the legality of shareholder rights plans for Israeli companies. The court indicated that it is inclined to view rights plans as permissible under Israeli law; that the adoption of a rights plan by a board should be viewed “with suspicion”; and that the board would bear the burden of proving certain matters related to the adoption of such a plan.

After Nano’s tender offer expired on July 31, 2023, the Tel-Aviv District Court decided that the litigation should be put on hold. On October 10, 2023, the court issued an order instructing the parties to inform it whether they consent to the dismissal of the claim and counter-claim, with no order for costs. On November 15, 2023, Nano informed the court that it requests to resume the proceedings. On December 19, 2023, the court issued an order noting that, from the parties' written submissions, it is appropriate to rule upon one critical question: whether, under Israeli law, a Company can adopt a ‘poison pill’ (i.e., a shareholder rights plan). The court further noted that Nano should consider either amending its claim or withdrawing it and filing a new one. The court emphasized that no new evidence will be allowed and that should Nano choose to proceed with the then-current action, the only question to be considered by the court is the validity of the poison pill under Israeli law. On July 1, 2024, following a request submitted by Nano, which was unopposed by the Company, the court dismissed Nano's claim without prejudice.

Ordinary course litigation

Note 13. Subsequent Events

In August 2024, the Company announced cost savings initiatives that includes a global workforce reduction. As a result of this restructuring plan, the Company expects $40 million of aggregate annualized cost savings. The Company anticipates that the 2024 this initiatives will be substantially complete by the end of 2024.

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

v3.24.2.u1

Document And Entity Information	6 Months Ended
	Jun. 30, 2024
DocumentAndEntityInformationAbstract
Document Type	6-K
Entity Registrant Name	STRATASYS LTD.
Entity Address, Address Line One	1 Holtzman Street,
Entity Address, Address Line Two	Science Park
Entity Address, Address Line Three	P.O. Box 2496
Entity Address, City or Town	Rehovot,
Entity Address, Country	IL
Entity Address, Postal Zip Code	76124
Entity Central Index Key	0001517396
Former Fiscal Year End Date	--12-31
Document Period End Date	Jun. 30, 2024
Amendment Flag	false

v3.24.2.u1

Consolidated Balance Sheets - USD ($) shares in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 70,858,000	$ 82,585,000	$ 144,366,000
Deposits Assets, Current	80,000,000	80,000,000
Accounts Receivable, after Allowance for Credit Loss, Current	150,483,000	172,009,000
Inventories	196,505,000	192,976,000
Prepaid expenses	8,570,000	7,929,000
Other current assets	17,575,000	24,596,000
Total current assets	523,991,000	560,095,000
Non-current assets
Property, plant and equipment, net	187,189,000	197,552,000
Goodwill	99,174,000	100,051,000
Other intangible assets, net	116,461,000	127,781,000
Operating lease right-of-use assets	17,928,000	18,895,000
Long-term investments	121,755,000	115,083,000
Other non-current assets	15,409,000	14,448,000
Total non-current assets	557,916,000	573,810,000
Total assets	1,081,907,000	1,133,905,000
Current liabilities
Accounts payable	49,495,000	46,785,000
Accrued expenses and other current liabilities	31,627,000	36,656,000
Employee related charges	26,666,000	33,877,000
Deferred revenues - short-term	50,914,000	52,610,000
Operating lease liabilities - short term	5,966,000	6,498,000
Total current liabilities	164,668,000	176,426,000
Non-current liabilities
Deferred revenues - long-term	18,880,000	23,655,000
Deferred income taxes	558,000	723,000
Operating lease liabilities - long term	11,780,000	12,162,000
Contingent consideration	11,851,000	11,900,000
Other non-current liabilities	23,699,000	24,200,000
Total non-current liabilities	66,768,000	72,640,000
Total liabilities	$ 231,436,000	249,066,000
Commitments and Contingencies Disclosure [Abstract]
Ordinary shares, authorized	180,000
Equity
Ordinary shares, NIS 0.01 nominal value, authorized 180,000 shares; 67,086 shares and 65,677 shares issued and outstanding at December 31, 2022 and 2021, respectively	$ 199,000	195,000
Additional paid-in capital	3,111,057,000	3,091,649,000
Accumulated other comprehensive loss	(9,133,000)	(7,079,000)	$ (12,671,000)	$ (12,818,000)
Accumulated deficit	(2,251,652,000)	(2,199,926,000)
Total equity	850,471,000	884,839,000
Total liabilities and equity	$ 1,081,907,000	$ 1,133,905,000

v3.24.2.u1

Consolidated Balance Sheets (Parentheticals) shares in Thousands, $ in Thousands	Jun. 30, 2024 USD ($) shares	Dec. 31, 2023 USD ($) shares
Statement of Financial Position [Abstract]
Accounts Receivable, Allowance for Credit Loss | $	$ 1,424	$ 1,449
Ordinary shares, authorized	180,000
Ordinary shares, outstanding	71,132	69,656

v3.24.2.u1

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues
Total net sales	$ 138,041	$ 159,751	$ 282,091	$ 309,128
Cost of revenues
Total cost of sales	77,541	93,529	157,694	177,511
Gross profit	60,500	66,222	124,397	131,617
Operating expenses
Research and development, net	25,680	24,305	49,657	45,780
Selling, general and administrative	60,863	75,576	125,236	136,293
Total operating expenses	86,543	99,881	174,893	182,073
Operating loss	(26,043)	(33,659)	(50,496)	(50,456)
Financial income (expenses), net	(726)	687	491	1,460
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total	(26,769)	(32,972)	(50,005)	(48,996)
Income tax benefit (expenses)	762	725	1,478	4,500
Share in net profits (losses) of associated companies	1,788	(4,918)	(243)	(7,343)
Net loss	$ (25,743)	$ (38,615)	$ (51,726)	$ (60,839)
Earnings Per Share, Basic	$ (0.36)	$ (0.56)	$ (0.74)	$ (0.89)
Weighted average shares outstanding - diluted	70,746	68,648	70,367	68,107
Comprehensive Loss
Net loss attributable to non-controlling interests	$ (25,743)	$ (38,615)	$ (51,726)	$ (60,839)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	(24)	579	(2,210)	1,834
Unrealized Gain (Loss) on Cash Flow Hedging Instruments	(526)	558	156	(1,687)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(550)	1,137	(2,054)	147
Comprehensive loss attributable to Stratasys Ltd.	(26,293)	(37,478)	(53,780)	(60,692)
Products
Revenues
Total net sales	93,594	109,112	192,790	210,083
Cost of revenues
Total cost of sales	46,756	57,576	96,513	108,689
Service [Member]
Revenues
Total net sales	44,447	50,639	89,301	99,045
Cost of revenues
Total cost of sales	$ 30,785	$ 35,953	$ 61,181	$ 68,822

v3.24.2.u1

Consolidated Statements of Changes in Equity - USD ($)	Total	Ordinary Shares	Additional Paid-In Capital	Accumulated Deficit	AOCI Attributable to Parent
Balance (in Shares) at Dec. 31, 2022		67,086,000
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2022	$ 959,432,000	$ 187,000	$ 3,048,915,000	$ (2,076,852,000)	$ (12,818,000)
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture		1,017,000
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	4,000	$ 3,000	1,000
Stock-based compensation	8,241,000		8,241,000
Comprehensive loss	(23,214,000)			(22,224,000)	(990,000)
Balance (in Shares) at Mar. 31, 2023		68,103,000
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2023	944,463,000	$ 190,000	3,057,157,000	(2,099,076,000)	(13,808,000)
Balance (in Shares) at Dec. 31, 2022		67,086,000
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2022	959,432,000	$ 187,000	3,048,915,000	(2,076,852,000)	(12,818,000)
Stock Issued During Period, Value, Employee Stock Purchase Plan	3,014,000
Balance (in Shares) at Jun. 30, 2023		68,942,000
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2023	923,227,000	$ 193,000	3,073,396,000	(2,137,691,000)	(12,671,000)
Balance (in Shares) at Mar. 31, 2023		68,103,000
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Mar. 31, 2023	944,463,000	$ 190,000	3,057,157,000	(2,099,076,000)	(13,808,000)
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture		268,000
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	5,000	$ 1,000	4,000
Stock-based compensation	8,022,000		8,022,000
Comprehensive loss	(37,478,000)			(38,615,000)	1,137,000
Stock Issued During Period, Value, Employee Stock Purchase Plan	$ 3,014,000	$ 1,000	3,013,000
Stock Issued During Period, Shares, Employee Stock Ownership Plan	253,000
Stock Issued During Period, Shares, New Issues	318,000
Balance (in Shares) at Jun. 30, 2023		68,942,000
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2023	$ 923,227,000	$ 193,000	3,073,396,000	(2,137,691,000)	(12,671,000)
Stock Issued During Period, Value, New Issues	5,201,000	1,000	5,200,000
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2023	884,839,000	$ 195,000	3,091,649,000	(2,199,926,000)	(7,079,000)
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture		784,000
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	149,000	$ 2,000	147,000
Stock-based compensation	8,649,000		8,649,000
Comprehensive loss	(27,487,000)			(25,983,000)	(1,504,000)
Balance (in Shares) at Mar. 31, 2024		70,440,000
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2024	866,150,000	$ 197,000	3,100,445,000	(2,225,909,000)	(8,583,000)
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2023	884,839,000	195,000	3,091,649,000	(2,199,926,000)	(7,079,000)
Stock Issued During Period, Value, Employee Stock Purchase Plan	3,264,000
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2024	850,471,000	199,000	3,111,057,000	(2,251,652,000)	(9,133,000)
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Mar. 31, 2024	866,150,000	$ 197,000	3,100,445,000	(2,225,909,000)	(8,583,000)
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture		249,000
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	4,000	$ 1,000	3,000
Stock-based compensation	7,346,000		7,346,000
Comprehensive loss	(26,293,000)			(25,743,000)	(550,000)
Stock Issued During Period, Value, Employee Stock Purchase Plan	$ 3,264,000	1,000	3,263,000
Stock Issued During Period, Shares, Employee Stock Ownership Plan	443,000
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2024	$ 850,471,000	$ 199,000	$ 3,111,057,000	$ (2,251,652,000)	$ (9,133,000)

v3.24.2.u1

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities
Net loss	$ (51,726)	$ (60,839)
Impairment of Long-Lived Assets to be Disposed of		919
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	23,781	24,343
Stock-based compensation	15,995	16,263
Foreign currency transaction loss (gain)	2,934	1,967
Share in net (profits) losses of associated companies	243	7,343
Unrealized Gain (Loss) on Investments	3,065	1,217
Acquisitions	1,034
Deferred income taxes, net and uncertain tax positions	369	2,810
Other non-cash items, net	761	2,073
Change in cash attributable to changes in operating assets and liabilities:
Accounts receivable, net	18,829	(11,156)
Inventories	(2,783)	(11,161)
Other current assets and prepaid expenses	5,900	(3,777)
Other non-current assets	3,049	4,642
Accounts payable	2,839	(4,360)
Other current liabilities	(7,323)	(8,972)
Deferred revenues	(5,805)	3,715
Other non-current liabilities	(6,261)	(6,194)
Net cash provided by (used in) operating activities	4,901	(41,167)
Cash flows from investing activities
Cash paid for business combinations, net of cash acquired	0	(66,472)
Purchase of property and equipment	(4,807)	(6,546)
Investments in short-term bank deposits	(50,000)	(12,448)
Proceeds from sale of equity method investment	50,000	128,815
Purchase of intangible assets	(1,142)	(464)
Other investing activities	(147)	(58)
Payments to Acquire Long-Term Investments	(8,845)	(6,199)
Net cash used in investing activities	(14,941)	36,628
Cash flows from financing activities
Proceeds from exercise of stock options	153	9
Payment of contingent consideration	(1,037)	(691)
Other financing activities	183	0
Net cash provided by (used in) financing activities	(701)	(682)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(987)	(824)
Net change in cash, cash equivalents and restricted cash	(11,728)	(6,045)
Cash, cash equivalents and restricted cash, beginning of year	82,864	150,686
Cash, cash equivalents and restricted cash, end of year	71,136	144,641
Non-cash investing and financing activities:
Transfer of inventories to fixed assets	1,658	5,612
Transfer of fixed assets to inventories	4,841	118
Stock Issued During Period, Value, Employee Stock Purchase Plan	3,264	3,014
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		3,009
Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:
Cash and cash equivalents	70,858	144,366
Restricted cash included in other current assets	278	275
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total	$ 71,136	$ 144,641

v3.24.2.u1

Consolidated Balance Sheets - USD ($)	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 70,858,000	$ 82,585,000	$ 144,366,000
Deposits Assets, Current	80,000,000	80,000,000
Accounts Receivable, after Allowance for Credit Loss, Current	150,483,000	172,009,000
Inventories	196,505,000	192,976,000
Prepaid expenses	8,570,000	7,929,000
Other current assets	17,575,000	24,596,000
Total current assets	523,991,000	560,095,000
Non-current assets
Property, plant and equipment, net	187,189,000	197,552,000
Goodwill	99,174,000	100,051,000
Other intangible assets, net	116,461,000	127,781,000
Operating lease right-of-use assets	17,928,000	18,895,000
Long-term investments	121,755,000	115,083,000
Other non-current assets	15,409,000	14,448,000
Total non-current assets	557,916,000	573,810,000
Total assets	1,081,907,000	1,133,905,000
Current liabilities
Accounts payable	49,495,000	46,785,000
Accrued expenses and other current liabilities	31,627,000	36,656,000
Employee related charges	26,666,000	33,877,000
Deferred revenues - short-term	50,914,000	52,610,000
Operating lease liabilities - short term	5,966,000	6,498,000
Total current liabilities	164,668,000	176,426,000
Non-current liabilities
Deferred revenues - long-term	18,880,000	23,655,000
Deferred income taxes	558,000	723,000
Operating lease liabilities - long term	11,780,000	12,162,000
Contingent consideration	11,851,000	11,900,000
Other non-current liabilities	23,699,000	24,200,000
Total non-current liabilities	66,768,000	72,640,000
Total liabilities	231,436,000	249,066,000
Equity
Ordinary shares, NIS 0.01 nominal value, authorized 180,000 shares; 67,086 shares and 65,677 shares issued and outstanding at December 31, 2022 and 2021, respectively	199,000	195,000
Additional paid-in capital	3,111,057,000	3,091,649,000
Accumulated other comprehensive loss	(9,133,000)	(7,079,000)	$ (12,671,000)	$ (12,818,000)
Accumulated deficit	(2,251,652,000)	(2,199,926,000)
Total equity	850,471,000	884,839,000
Total liabilities and equity	$ 1,081,907,000	$ 1,133,905,000

v3.24.2.u1

Consolidated Balance Sheets (Parentheticals) shares in Thousands	Jun. 30, 2024 ₪ / shares shares
Statement of Financial Position [Abstract]
Ordinary shares, nominal value (in Dollars per share) | ₪ / shares	₪ 0.01
Ordinary shares, authorized	180,000
Ordinary shares, outstanding	71,132

v3.24.2.u1

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues
Total net sales	$ 138,041	$ 159,751	$ 282,091	$ 309,128
Cost of revenues
Total cost of sales	77,541	93,529	157,694	177,511
Gross profit	60,500	66,222	124,397	131,617
Operating expenses
Research and development, net	25,680	24,305	49,657	45,780
Selling, general and administrative	60,863	75,576	125,236	136,293
Total operating expenses	86,543	99,881	174,893	182,073
Operating loss	(26,043)	(33,659)	(50,496)	(50,456)
Financial income (expenses), net	(726)	687	491	1,460
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total	(26,769)	(32,972)	(50,005)	(48,996)
Income tax benefit (expenses)	762	725	1,478	4,500
Share in net profits (losses) of associated companies	1,788	(4,918)	(243)	(7,343)
Net loss	$ (25,743)	$ (38,615)	$ (51,726)	$ (60,839)
Earnings Per Share, Basic	$ (0.36)	$ (0.56)	$ (0.74)	$ (0.89)
Weighted average shares outstanding - diluted	70,746	68,648	70,367	68,107
Comprehensive Loss
Net loss attributable to non-controlling interests	$ (25,743)	$ (38,615)	$ (51,726)	$ (60,839)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	(24)	579	(2,210)	1,834
Unrealized Gain (Loss) on Cash Flow Hedging Instruments	(526)	558	156	(1,687)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(550)	1,137	(2,054)	147
Comprehensive loss attributable to Stratasys Ltd.	(26,293)	(37,478)	(53,780)	(60,692)
Products
Revenues
Total net sales	93,594	109,112	192,790	210,083
Cost of revenues
Total cost of sales	46,756	57,576	96,513	108,689
Service [Member]
Revenues
Total net sales	44,447	50,639	89,301	99,045
Cost of revenues
Total cost of sales	$ 30,785	$ 35,953	$ 61,181	$ 68,822

v3.24.2.u1

Consolidated Statements of Changes in Equity - USD ($) shares in Thousands, $ in Thousands	Total	Ordinary Shares	Additional Paid-In Capital	Accumulated Deficit	AOCI Attributable to Parent
Balance (in Shares) at Dec. 31, 2022		67,086
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2022	$ 959,432	$ 187	$ 3,048,915	$ (2,076,852)	$ (12,818)
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture		1,017
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	4	$ 3	1
Stock-based compensation	8,241		8,241
Comprehensive loss	(23,214)			(22,224)	(990)
Balance (in Shares) at Mar. 31, 2023		68,103
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2023	944,463	$ 190	3,057,157	(2,099,076)	(13,808)
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture		268
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	5	$ 1	4
Stock-based compensation	8,022		8,022
Comprehensive loss	(37,478)			(38,615)	1,137
Balance (in Shares) at Jun. 30, 2023		68,942
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2023	923,227	$ 193	3,073,396	(2,137,691)	(12,671)
Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2023	884,839	$ 195	3,091,649	(2,199,926)	(7,079)
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture		784
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	149	$ 2	147
Stock-based compensation	8,649		8,649
Comprehensive loss	(27,487)			(25,983)	(1,504)
Balance (in Shares) at Mar. 31, 2024		70,440
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2024	866,150	$ 197	3,100,445	(2,225,909)	(8,583)
Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture		249
Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture	4	$ 1	3
Stock-based compensation	7,346		7,346
Comprehensive loss	(26,293)			(25,743)	(550)
Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Jun. 30, 2024	$ 850,471	$ 199	$ 3,111,057	$ (2,251,652)	$ (9,133)

v3.24.2.u1

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities
Net loss	$ (51,726)	$ (60,839)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	23,781	24,343
Stock-based compensation	15,995	16,263
Foreign currency transaction loss (gain)	2,934	1,967
Share in net (profits) losses of associated companies	243	7,343
Unrealized Gain (Loss) on Investments	3,065	1,217
Acquisitions	1,034
Deferred income taxes, net and uncertain tax positions	369	2,810
Other non-cash items, net	761	2,073
Change in cash attributable to changes in operating assets and liabilities:
Accounts receivable, net	18,829	(11,156)
Inventories	(2,783)	(11,161)
Other current assets and prepaid expenses	5,900	(3,777)
Other non-current assets	3,049	4,642
Accounts payable	2,839	(4,360)
Other current liabilities	(7,323)	(8,972)
Deferred revenues	(5,805)	3,715
Other non-current liabilities	(6,261)	(6,194)
Net cash provided by (used in) operating activities	4,901	(41,167)
Cash flows from investing activities
Cash paid for business combinations, net of cash acquired	0	(66,472)
Purchase of property and equipment	(4,807)	(6,546)
Investments in short-term bank deposits	(50,000)	(12,448)
Proceeds from sale of equity method investment	50,000	128,815
Purchase of intangible assets	(1,142)	(464)
Other investing activities	(147)	(58)
Payments to Acquire Long-Term Investments	(8,845)	(6,199)
Net cash used in investing activities	(14,941)	36,628
Cash flows from financing activities
Proceeds from exercise of stock options	153	9
Payment of contingent consideration	(1,037)	(691)
Other financing activities	183	0
Net cash provided by (used in) financing activities	(701)	(682)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(987)	(824)
Net change in cash, cash equivalents and restricted cash	(11,728)	(6,045)
Cash, cash equivalents and restricted cash, beginning of year	82,864	150,686
Cash, cash equivalents and restricted cash, end of year	71,136	144,641
Non-cash investing and financing activities:
Transfer of inventories to fixed assets	1,658	5,612
Transfer of fixed assets to inventories	4,841	118
Reconciliation of cash, cash equivalents and restricted cash reported in the consolidated balance sheets:
Cash and cash equivalents	70,858	144,366
Restricted cash included in other current assets	278	275
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total	$ 71,136	$ 144,641

v3.24.2.u1

Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure	Note 1. Business Description and Basis of Presentation  Stratasys Ltd. (collectively with its subsidiaries, the “Company” or “Stratasys”) is a global leader in connected, polymer-based 3D printing solutions, across the entire manufacturing value chain. The Company leverages its competitive advantages, which include a broad set of best-in-class 3D printing platforms, software, a materials and technology partner ecosystem, innovative leadership, and global GTM infrastructure, in order to position itself to capture share in a significant and growing global marketplace, with a focus on manufacturing, which the Company views as having the largest and fastest growing total addressable market. The Company’s approximately 2,600 granted and pending additive technology patents to date have been used to create models, prototypes, manufacturing tools, and production parts for a multitude of industries including aerospace, automotive, transportation, healthcare, consumer products, dental, medical, fashion and education. Stratasys’ products and comprehensive solutions improve product quality, development time, cost, time-to-market and patient care. The Company’s 3D ecosystem of solutions and expertise includes 3D printers, materials, software, expert services, and on-demand parts production. The condensed consolidated interim financial information herein is unaudited; however, such information reflects all adjustments (consisting of normal, recurring adjustments), which are, in the opinion of management, necessary for a fair statement of results for the interim period. The condensed consolidated interim financial statements include the accounts of Stratasys Ltd. and its subsidiaries. All intercompany accounts and transactions, including profits from intercompany sales not yet realized outside the Company, have been eliminated in consolidation. The Company’s financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), which require the Company to make estimates based on assumptions about current and, for some estimates, future economic and market conditions which affect reported amounts and related disclosures in its financial statements. Although the Company’s current estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from the Company’s expectations, which could materially affect its results of operations and financial position. In particular, a number of estimates have been and will continue to be affected by global events and other longer-term macroeconomic conditions, most prominently, the extent and speed at which inflation subsides, whether and when interest rates are reduced by central banks, whether and when tight credit conditions are loosened, whether capital markets continue to rise and whether global supply chains remain open. As a result, the accounting estimates and assumptions may change over time. Such changes could have an additional impact on the Company’s long-lived asset, goodwill and intangible asset valuations; and the allowance for expected credit losses. These consolidated financial statements reflect the financial statement effects based upon management’s estimates and assumptions utilizing the most currently available information.  In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these financial statements, the war in Israel is ongoing and continues to evolve. One of the Company’s global headquarters and one of its manufacturing facilities are located in Israel. As of the publication date of these financial statements, the Company's activities in Israel remain largely unaffected by the war. During the six months ended June 30, 2024, the impact of the war on the Company’s results of operations and financial condition was limited, but such impact may change, and could be significant, as a result of the continuation, escalation or expansion of the war. The Company continues to maintain business continuity plans backed by its inventory levels located outside of Israel. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain financial information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. The reader is referred to the Company's audited consolidated financial statements and notes thereto for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 11, 2024 as part of the Company’s Annual Report on Form 20-F for such year.
Accounting Standards Update and Change in Accounting Principle	Note 2. New Accounting Pronouncements     Recently issued accounting pronouncements, not yet adopted In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements related disclosures. In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

v3.24.2.u1

Certain Transactions	6 Months Ended
	Jun. 30, 2024
Certain Transactions [Abstract]
Certain Transactions	Note 3. Certain Transactions   Covestro acquisition On April 3, 2023 (the “Covestro transaction date”), the Company completed the acquisition of the additive manufacturing materials business of Covestro AG. Covestro’s additive manufacturing business is expected to give the Company the ability to accelerate innovative developments in 3D printing materials and to thereby further grow adoption of its newest technologies. Also, the Company acquired an IP portfolio comprised of hundreds of patents and pending patents, including all of the SOMOS™ portfolio. The Covestro transaction is reflected in accordance with ASC Topic 805, “Business Combinations”. The assets acquisition transaction meets the definition of a business and was accounted for as a “Business Combinations” transaction, using the acquisition method of accounting with the Company as the acquirer. The following table summarizes the fair value of the consideration transferred to Covestro AG for the Covestro transaction: U.S. $ in thousands Cash payments $ 53,815  Issuance of ordinary shares to Covestro stockholders     5,202  Contingent consideration at estimated fair value 659  Other liability 868  Total consideration $ 60,544  The fair value of the ordinary shares issued was determined based on the closing market price of the Company's ordinary shares on the Covestro transaction date. In accordance with ASC Topic 805, the estimated contingent consideration as of the Covestro transaction date was included in the purchase price. The total contingent payments could amount to a maximum aggregate amount of up to €37 million. The payment will be settled through the issuance of ordinary shares. The estimated fair value of the contingent consideration is based on management’s assessment of whether, and at what level, the financial metrics will be achieved, and the present value factors associated with the timing of the payments. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. Changes in the fair value of contingent consideration will be recorded in operating expenses. Refer to Note 9. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the Covestro transaction date. The estimated fair values are based on the information that was available as of April 3, 2023. The allocation of the purchase price to assets acquired and liabilities assumed is as follows: Allocation of Purchase Price U.S. $ in thousands Inventory $ 10,342  Fixed assets 7,064  Intangible assets 21,929  Other liabilities (605) Total identifiable net assets 38,730  Goodwill 21,814  Total consideration $ 60,544  The allocation of the PPA to net assets acquired and liabilities assumed resulted in the recognition of intangible assets related to developed technology, customer relationship, and trade name. These intangible assets have a useful life of 7 to 10 years. The fair value estimate of the customer relationship was determined using a variation of the income approach known as the “Multi-Period Excess Earnings Approach”. This valuation technique estimates the fair value of an asset based on market participants’ expectations of the cash flows the asset would generate over its remaining useful life. The net cash flows were discounted to present value. The fair value estimate of the developed technology and trade name, were estimated using the "Relief from royalty" method. This valuation technique estimates the fair value of the asset based on the hypothetical royalty payment that a licensee would be required to pay in exchange for use of the asset. Goodwill was recorded as the residual amount by which the purchase price exceeded the provisional fair value of the net assets acquired and is expected to be fully deductible for tax purposes. Goodwill consists primarily of expected synergies of combining operations, the acquired workforce, and growth opportunities, none of which qualify as separately identifiable intangible assets. Pro forma information giving effect to the acquisition has not been provided, as the results would not be material. During 2023, the Company completed several transactions, including acquisitions of an entity and additional assets, for a total consideration of $22 million. MakerBot and Ultimaker transaction ("Ultimaker") On August 31, 2022, Stratasys completed the merger of MakerBot (previously, a wholly-owned subsidiary) with Ultimaker, which together formed a new entity under the name Ultimaker. The Company accounts for its investment in the combined company Ultimaker according to the equity method in accordance with ASC Topic 323, as it has retained the ability to exercise significant influence but does not control the new entity. The Company recognized an equity method investment in a total amount of $105.6 million comprised of the assumed fair value of the MakerBot shares and additional amount invested in cash by the Company, representing a share of 46.5% in the new entity. During 2023, Ultimaker encountered difficulties in its business partially as a result of tighter competition and global market conditions. As a result, senior management at Ultimaker was replaced and the new management implemented a restructuring plan and additional steps to reduce cost and improve profitability. The Company considered such events as indicators of potential impairment and accordingly performed an impairment analysis for the investment in Ultimaker. Based on such valuation, the fair value of the investment was estimated below its carrying amount and such reduction in fair value was determined to be other than temporary. Accordingly the Company recorded an impairment charge in an amount of $13.9 million, which was recorded in share in losses of associated companies in the consolidated statements of operations and comprehensive loss. Management’s cash flow projections for the fair value of the investment in Ultimaker include significant judgments and assumptions relating to the cash flow projections, future growth and future profitability. Actual results could differ from those estimates, and such differences could be material and may result in other than temporary reduction in fair value, which could lead to additional impairments in the carrying value of the Ultimaker investment. On March 22, 2024, Ultimaker's shareholders agreed to provide it with additional funding of $8.0 million in cash, out of which $4.5 million was funded by the Company during the six months ended June 30, 2024. As of June 30, 2024 and December 31, 2023 the Company's equity investment in Ultimaker amounted to $72.2 million and $67.8 million, respectively, which represents the Company's investment in Ultimaker, net of the Company's share in Ultimaker's net losses for the respective periods in amounts of $0.1 million and $32.4 million, respectively. Other long-term investments In addition to the investment in Ultimaker, other investments included under Long-term investments represent investments in non-marketable equity securities and convertible notes of several companies without readily determinable fair value in which the Company does not have a controlling interest or significant influence. During the six months ended June 30, 2024 and during 2023, the Company invested a total of $5.4 million and $11.5 million, respectively, in non-marketable equity securities and convertible notes of several companies.

v3.24.2.u1

Revenues	6 Months Ended
	Jun. 30, 2024
Revenue Recognition [Abstract]
Revenues	Note 4. Revenues Disaggregation of Revenues The following table presents the Company’s revenues disaggregated by geographical region (based on the Company's customers' locations) and revenue type for the three and six months ended June 30, 2024 and 2023: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 (U.S. $ in thousands) (U.S. $ in thousands) Americas Systems $ 14,054  $ 28,975  $ 32,047  $ 50,161  Consumables 36,182  33,757  71,724  66,329  Service 33,252  39,463  66,525  75,785  Total Americas 83,488  102,195  170,296  192,275  EMEA Systems 9,800  12,054  19,523  23,456  Consumables 19,945  17,910  41,115  36,821  Service 7,308  6,920  14,888  14,487  Total EMEA 37,053  36,884  75,526  74,764  Asia Pacific Systems 5,125  7,284  10,294  15,148  Consumables 8,488  9,132  18,087  18,168  Service 3,887  4,256  7,888  8,773  Total Asia Pacific 17,500  20,672  36,269  42,089  Total Revenues $ 138,041  $ 159,751  $ 282,091  $ 309,128  The following table presents the Company’s revenues disaggregated based on the timing of revenue recognition (at a specific point in time or over the course of time) for the three and six months ended June 30, 2024 and 2023: Three Months Ended June 30, six months ended June 30, 2024 2024 2023 2024 2023 (U.S. $ in thousands) (U.S. $ in thousands) Revenues recognized in point in time from: Products $ 93,594  $ 109,112  $ 192,790  $ 210,083  Services 12,847  14,156  26,619  27,847  Total revenues recognized in point in time 106,441  123,268  219,409  237,930  Revenues recognized over time from: Services 31,600  36,483  62,682  71,198  Total revenues recognized over time 31,600  36,483  62,682  71,198  Total Revenues $ 138,041  $ 159,751  $ 282,091  $ 309,128  Contract Assets and Contract Liabilities Contract assets are recorded when the Company's right to consideration is conditioned on constraints other than the passage of time. The Company had no material contract assets as of June 30, 2024 and December 31, 2023. Contract liabilities include advance payments and billings in excess of revenue recognized, which are primarily related to advanced billings for service type warranty. Contract liabilities are presented under deferred revenue. The Company's deferred revenue as of June 30, 2024 and December 31, 2023 was as follows: June 30, December 31, 2024 2023 U.S. $ in thousands Deferred revenue * $ 69,794  $ 76,265  *Includes $18.9 million and $23.7 million under long-term deferred revenue in the Company's consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively. Revenue recognized in 2024 that was included in deferred revenue balance as of December 31, 2023 was $14.5 million and $33.1 million  for the three and six months ended June 30, 2024, respectively. Remaining Performance Obligations Remaining Performance Obligations (“RPO“) represent contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. As of June 30, 2024, the total RPO amounted to $98.3 million. The Company expects to recognize $68.0 million of this RPO during the next 12 months, $14.7 million over the subsequent 12 months and the remaining $15.6 million thereafter. Incremental Costs of Obtaining a Contract Sales commissions earned mainly by the Company’s sales agents are considered incremental costs of obtaining a contract with a customer, as the Company expects the benefit of those commissions to be longer than one year. The majority of the sales commissions are not subject to capitalization, as the commission expense is recognized as the related revenue is recognized. Sales commissions for initial contracts related to the service type warranty are deferred and then amortized on a straight-line basis over the expected customer relationship period if the Company expects to recover those costs. Amortization expense is included in selling, general and administrative expenses in the consolidated statements of operations. As of June 30, 2024 and December 31, 2023, the deferred commissions amounted to $10.3 million and $10.3 million, respectively.

v3.24.2.u1

Inventories	6 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Inventories	Note 5. Inventories Inventories consisted of the following: June 30, 2024 December 31, 2023 U.S. $ in thousands Finished goods $ 95,670  $ 86,908  Work-in-process 9,870  9,871  Raw materials 90,965  96,197  $ 196,505  $ 192,976

v3.24.2.u1

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2024
Disclosure Text Block Supplement [Abstract]
Goodwill and Intangible Assets Disclosure	Note 6. Goodwill and Other Intangible Assets  Goodwill Changes in the carrying amount of the Company’s goodwill during the six months ended June 30, 2024 were as follows: U.S. $ in thousands Goodwill as of January 1, 2024 $ 100,051  Foreign currency translation adjustments (877) Goodwill as of June 30, 2024 $ 99,174  During the fourth quarter of 2023, the Company performed its annual impairment test for goodwill impairment. The Company performed a quantitative assessment for goodwill impairment for its Stratasys-Core reporting unit and concluded that the fair value of Stratasys-Core reporting unit exceeded its carrying amount by approximately 34%, with a carrying amount of goodwill assigned to this reporting unit in an amount of $100.0 million. When evaluating the fair value of Stratasys-Core reporting unit under the income approach, the Company used a discounted cash flow model which utilized Level 3 measures that represent unobservable inputs. Key assumptions used to determine the estimated fair value include: (a) internal cash flows forecasts for 4 years following the assessment date, including expected revenue growth, costs to produce, operating profit margins and estimated capital needs; (b) an estimated terminal value using a terminal year long- term future growth determined based on the growth prospects of the reporting unit; and (c) a discount rate which reflects the weighted average cost of capital adjusted for the relevant risk associated with the Stratasys-Core reporting unit operations and the uncertainty inherent in the Company's internally developed forecasts. In order to assess the reasonableness of its cash flow projections used for its goodwill impairment analysis, the Company compared the aggregate fair value of its reporting units to its market capitalization and calculated the implied control premium. The Company believes that its fair value assessment is reasonably supported by its calculated market capitalization. Actual results may differ from those assumed in the Company's valuation method. It is reasonably possible that the Company's assumptions described above could change in future periods. If any of these were to vary materially from the Company's plans, it may record impairment of goodwill allocated to this reporting unit in the future. Based on the Company’s assessment as of December 31, 2023, no goodwill was determined to be impaired. During the second quarter of 2024, the Company performed an analysis of the impact of recent events, including business and industry specific considerations, on the fair value of Stratasys-Core reporting unit. As part of this analysis the Company considered the changes in market capitalization and the sensitivity of estimates and assumptions used in the last annual impairment test as well as potential impacts of macro-economic pressure. The Company also analyzed the aggregate fair value of its reporting units compared to its market capitalization as part of its goodwill impairment test, in order to assess the reasonableness of the results of its cash flow projections used for its goodwill impairment analysis. The Company noted its market capitalization was below management’s assessment of the aggregate fair value of its reporting units. However, as of June 30, 2024, the Company’s market capitalization plus a reasonable control premium exceeded its book value. While management believes the goodwill of the reporting unit is currently not impaired, there can be no assurances that goodwill will not be impaired in future periods. The Company will continue to monitor the fair value of its Stratasys-Core reporting unit to determine whether events and changes in circumstances such as further deterioration in the business climate or operating results, significant decline in the Company's share price, changes in management’s business strategy or downward changes of the Company's cash flows projections, warrant further interim impairment testing. Other Intangible Assets Other intangible assets consisted of the following: June 30, 2024 December 31, 2023 Carrying Amount, net of Impairment Accumulated Amortization Net book value   Carrying Amount, net of Impairment Accumulated Amortization Net book value U.S. $ in thousands Developed technology $ 403,035  $ (309,542) $ 93,493  $ 403,180  $ (300,780) $ 102,400  Patents 20,975  (11,041) 9,934  19,396  (10,246) 9,150  Trademarks and trade names 22,161  (16,940) 5,221  22,286  (15,936) 6,350  Customer relationships 102,634  (94,821) 7,813  102,520  (92,639) 9,881  Capitalized software development costs 3,236  (3,236) —  4,367  (4,367) —  $ 552,041  $ (435,580) $ 116,461  $ 551,749  $ (423,968) $ 127,781  Amortization expenses relating to intangible assets for the three-month periods ended June 30, 2024 and 2023 were approximately $5.7 million and $7.1 million, respectively. Amortization expenses relating to intangible assets for the six-month periods ended June 30, 2024 and 2023 were approximately $12.6 million and $13.3 million, respectively. As of June 30, 2024, the estimated amortization expenses relating to intangible assets for each of the following future periods were as follows: Estimated amortization expenses (U.S. $ in thousands) Remaining 6 months of 2024 $ 11,245  2025 21,336 2026 21,247 2027 20,320 2028 16,290 2029 and thereafter 26,023 Total $ 116,461

v3.24.2.u1

Net Loss per Share	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Net loss per Share	Note 7. Net Loss Per Share The following table presents the numerator and denominator of the basic and diluted net loss per share computations for the three and six months ended June 30, 2024 and 2023: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 In thousands, except per share amounts In thousands, except per share amounts Numerator: Net loss for basic and diluted net loss per share $ (25,743) $ (38,615) $ (51,726) $ (60,839) Denominator: Weighted average shares - for basic and diluted net loss per share 70,746  68,648  70,367  68,107  Net loss per share Basic and diluted $ (0.36) $ (0.56) $ (0.74) $ (0.89)  The computation of diluted net loss per share excluded share awards of 5.5 million shares and 3.0 million million shares for the three months ended June 30, 2024 and 2023 respectively, because the inclusion of those shares would have had an anti-dilutive effect on the diluted net loss per share.  The computation of diluted net loss per share excluded share awards of 3.9 million shares and 3.3 million shares for the six months ended June 30, 2024 and 2023 respectively, because the inclusion of those shares would have had an anti-dilutive effect on the diluted net loss per share.

v3.24.2.u1

Income Taxes	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company had income tax expenses of $0.8 million for the three-month period ended June 30, 2024, compared to income tax expenses of $0.7 million for the three-month period ended June 30, 2023. The Company had income tax expenses of $1.5 million for the six-month period ended June 30, 2024, compared to income tax expenses of $4.5 million for the six-month period ended June 30, 2023. The Company’s effective tax rate as of June 30, 2024, was primarily impacted by the geographic mix of its earnings and losses, movements in its valuation allowance and changes in its uncertain tax positions.

v3.24.2.u1

Fair Value Measurement	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurement	Note 9. Fair Value Measurements The following table summarizes the Company’s financial assets and liabilities that are carried at fair value on a recurring basis, in its consolidated balance sheets: June 30, 2024 December 31, 2023 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 (U.S. $ in thousands) Assets: Foreign exchange forward contracts not designated as hedging instruments $ —  $ 82  $ —  $ —  $ 164  $ —  Foreign exchange forward contracts designated as hedging instruments —  1,485  —  —  2,087  —  Convertible notes —  —  8,786  —  —  7,018  Marketable securities 828  1,994  —  —  Liabilities: Foreign exchange forward contracts not designated as hedging instruments —  (31) —  —  (51) —  Foreign exchange forward contracts designated as hedging instruments —  (47) —  —  (657) —  Contingent consideration* —  —  (18,371) —  —  (18,603) $ 828  $ 1,489  $ (9,585) $ 1,994  $ 1,543  $ (11,585) *Includes $6.5 million and $6.7 million under accrued expenses and other current liabilities in the Company's consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively. The Company's foreign exchange forward contracts are classified as Level 2, as they are not actively traded and are valued using pricing models that use observable market inputs, including interest rate curves and both forward and spot prices for currencies (Level 2 inputs). Contingent consideration represents liabilities recorded at fair value in connection with acquisitions, and thus represents a Level 3 measurement within the fair value hierarchy (refer to Note 3). Other financial instruments consist mainly of cash and cash equivalents, short-term deposits, current and non-current receivables, accounts payable and other current liabilities. The fair value of these financial instruments approximates their carrying values.

v3.24.2.u1

Derivatives and Hedging Activities	3 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Note 10. Derivative instruments and hedging activities Since the Company conducts its operations globally, it is exposed to global market risks and to the risk that its earnings, cash flows and equity could be adversely impacted by fluctuations in foreign currency exchange rates. The Company enters into transactions involving foreign currency exchange derivative financial instruments. The Company manages its foreign currency exposures on a consolidated basis, which allows the Company to net exposures and take advantage of any natural hedging. The transactions are designed to manage the Company’s net exposure to foreign currency exchange rates and to reduce the volatility of earnings and cash flows associated with changes in foreign currency exchange rates. The Company does not enter into derivative transactions for trading purposes. The Company is primarily exposed to foreign exchange risk with respect to recognized assets and liabilities and forecasted transactions denominated in the New Israeli Shekel (“NIS”), Euro, British Pound, Korean Won, Chinese Yuan and the Japanese Yen. The gains and losses on the hedging instruments partially offset losses and gains on the hedged items. Financial markets and currency volatility may limit the Company’s ability to hedge these exposures. These contracts mature through December 2024. The following table summarizes the consolidated balance sheets classification and fair values of the Company’s derivative instruments: Fair Value Notional Amount Balance sheet location June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 U.S. $ in thousands Assets derivatives -Foreign exchange contracts, not designated as hedging instruments Other current assets $ 82  $ 164  $ 35,581  $ 82,873  Assets derivatives -Foreign exchange contracts, designated as cash flow hedge Other current assets 1,485  2,087  54,152  51,830  Liability derivatives -Foreign exchange contracts, not designated as hedging instruments Accrued expenses and other current liabilities (31) (51) 47,237  21,168  Liability derivatives -Foreign exchange contracts, designated as cash flow hedge Accrued expenses and other current liabilities (47) (657) 13,066  74,054  $ 1,489  $ 1,543  $ 150,036  $ 229,925  Foreign exchange contracts not designated as hedging instruments As of June 30, 2024, the notional amounts of the Company’s outstanding exchange forward contracts, not designated as hedging instruments, were $82.8 million, and were used to reduce foreign currency exposures of the Euro, New Israeli Shekel (the "NIS"), British Pound, Japanese Yen, Korean Won and Chinese Yuan. With respect to such derivatives, a gain of $0.5 million and a gain of $1.6 million were recognized under financial expenses, net for the three-month periods ended June 30, 2024 and 2023, respectively and a gain of $1.8 million and a gain of $1.2 million million were recognized under financial expenses, net for the six-month periods ended June 30, 2024 and 2023, respectively. Such gains partially offset the revaluation losses of the balance sheet items which are also recognized under financial income (expenses), net. Cash Flow Hedging - Hedges of Forecasted Foreign Currency Payroll and other operating expenses As of June 30, 2024, the Company had in effect foreign exchange forward contracts, designated as cash flow hedges for accounting purposes, for the conversion of $27.3 million into NIS. The Company uses short-term cash flow hedge contracts to reduce its exposure to variability in expected future cash flows resulting mainly from payroll costs denominated in New Israeli Shekels. The changes in fair value of those contracts are included in the Company’s accumulated other comprehensive loss. Cash Flow Hedging - Hedges of Forecasted Foreign Currency Revenue The Company transacts business in U.S. Dollars and in various other currencies. The Company may use foreign exchange or forward contracts to hedge certain cash flow exposures resulting from changes in these foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities of up to twelve months. The Company enters into these foreign exchange contracts to hedge a portion of its forecasted foreign currency denominated revenue in the normal course of business, and accordingly, they are not speculative in nature. As of June 30, 2024, the Company had in effect foreign exchange forward contracts, designated as cash flow hedges for accounting purposes, for the conversion of €36.0 million into dollars.

v3.24.2.u1

Equity	6 Months Ended
	Jun. 30, 2024
Stockholders' Equity Note [Abstract]
Equity	Note 11. Equity a. Stock-based compensation plans Stock-based compensation expenses for equity-classified stock options, restricted share units (“RSUs”) and performance-based restricted share units (”PSUs”) were allocated as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 U.S $ in thousands U.S $ in thousands Cost of revenues $ 1,010  $ 999  $ 1,962  $ 1,931  Research and development, net 2,120  1,867  4,251  3,956  Selling, general and administrative 4,216  5,156  9,782  10,376  Total stock-based compensation expenses $ 7,346  $ 8,022  $ 15,995  $ 16,263  A summary of the Company’s stock option activity for the six months ended June 30, 2024 is as follows: Number of Options Weighted Average Exercise Price Options outstanding as of January 1, 2024 1,360,652  20.67  Granted —  —  Exercised (12,413) 12.30  Forfeited (54,569) 24.30  Options outstanding as of June 30, 2024 1,293,670  20.60  Options exercisable as of June 30, 2024 1,014,148  21.80  As of June 30, 2024, the unrecognized compensation cost of $0.3 million related to all unvested, equity-classified stock options is expected to be recognized as an expense over a weighted-average period of 1.56 years. A summary of the Company’s RSUs and PSUs activity for the six months ended June 30, 2024 is as follows: Number of RSUs and PSUs Weighted Average Grant Date Fair Value Unvested as of January 1, 2024 3,842,232  17.95  Granted 1,867,931  11.77  Vested (1,020,493) 19.12  Forfeited (213,697) 19.14  Unvested as of June 30, 2024 4,475,973  18.83  The fair value of RSUs and PSUs is determined based on the quoted price of the Company’s ordinary shares on the date of the grant. As of June 30, 2024, the unrecognized compensation cost of $55.7 million related to all unvested, equity-classified RSUs and PSUs is expected to be recognized as expense over a weighted-average period of 2.79 years. b. Accumulated other comprehensive loss The following tables present the changes in the components of accumulated other comprehensive income (loss), net of taxes, for the six months ended June 30, 2024 and 2023, respectively: Six Months Ended June 30, 2024 Net Unrealized Gain (Loss) on Cash Flow Hedges Foreign Currency Translation Adjustments Total U.S. $ in thousands Balance as of January 1, 2024 $ 1,790  $ (8,869) $ (7,079) Other comprehensive income (loss) before reclassifications 1,459  (2,210) (751) Amounts reclassified from accumulated other comprehensive loss (1,303) —  (1,303) Other comprehensive loss 156  (2,210) (2,054) Balance as of June 30, 2024 $ 1,946  $ (11,079) $ (9,133) Six Months Ended June 30, 2023 Net Unrealized Gain (Loss) on Cash Flow Hedges Foreign Currency Translation Adjustments Total U.S. $ in thousands Balance as of January 1, 2023 $ (299) $ (12,519) $ (12,818) Other comprehensive income before reclassifications (2,708) 1,834  (874) Amounts reclassified from accumulated other comprehensive loss 1,021  —  1,021  Other comprehensive income (1,687) 1,834  147  Balance as of June 30, 2023 $ (1,986) $ (10,685) $ (12,671)

v3.24.2.u1

Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 12. Contingencies Legal proceedings Litigation with Nano Dimension regarding Stratasys’ Rights Plan and Nano Dimension’s tender offer On April 25, 2023, the Company was named as a defendant in an action filed by Nano in the Tel-Aviv District Court in which Nano sought declaratory relief declaring that Stratasys’ shareholder rights plan is both illegal and void, and also requested a court order enjoining the Company and its directors from intervening with, or hindering in any way, a tender offer that Nano at the time intended to launch to acquire Stratasys ordinary shares. On June 8, 2023, in its statement of defense, the Company rejected all of Nano’s claims, stating, among other things, that there was a substantial change of circumstance since Nano’s action was filed due to Stratasys’ entry into the Desktop Metal Merger Agreement on May 25, 2023 and the launch of Nano’s tender offer on May 25, 2023. The Company argued that its rights plan is legal under Israeli law, and that due to the many flaws and unlawful conditions of Nano’s tender offer and Nano’s conduct and circumstances, The Company’s board was obligated to get involved and protect the Company and its shareholders. The Company also submitted a counterclaim to the court, seeking an order restraining Nano from completing its tender offer until certain conditions were to be fulfilled. On July 18, 2023, in the context of an interim procedural decision, the Israeli court took the opportunity to express its preliminary view on the legality of shareholder rights plans for Israeli companies. The court indicated that it is inclined to view rights plans as permissible under Israeli law; that the adoption of a rights plan by a board should be viewed “with suspicion”; and that the board would bear the burden of proving certain matters related to the adoption of such a plan. After Nano’s tender offer expired on July 31, 2023, the Tel-Aviv District Court decided that the litigation should be put on hold. On October 10, 2023, the court issued an order instructing the parties to inform it whether they consent to the dismissal of the claim and counter-claim, with no order for costs. On November 15, 2023, Nano informed the court that it requests to resume the proceedings. On December 19, 2023, the court issued an order noting that, from the parties' written submissions, it is appropriate to rule upon one critical question: whether, under Israeli law, a Company can adopt a ‘poison pill’ (i.e., a shareholder rights plan). The court further noted that Nano should consider either amending its claim or withdrawing it and filing a new one. The court emphasized that no new evidence will be allowed and that should Nano choose to proceed with the then-current action, the only question to be considered by the court is the validity of the poison pill under Israeli law. On July 1, 2024, following a request submitted by Nano, which was unopposed by the Company, the court dismissed Nano's claim without prejudice. Ordinary course litigation In addition to the foregoing litigations, the Company is also a party to various legal proceedings from time to time, the outcome of which, in the opinion of management, will not have a significant effect on the financial position, profitability or cash flows of the Company.
Subsequent Events	Note 13. Subsequent Events In August 2024, the Company announced cost savings initiatives that includes a global workforce reduction. As a result of this restructuring plan, the Company expects $40 million of aggregate annualized cost savings. The Company anticipates that the 2024 this initiatives will be substantially complete by the end of 2024.

v3.24.2.u1

Accounting Policies	6 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure	Note 1. Business Description and Basis of Presentation  Stratasys Ltd. (collectively with its subsidiaries, the “Company” or “Stratasys”) is a global leader in connected, polymer-based 3D printing solutions, across the entire manufacturing value chain. The Company leverages its competitive advantages, which include a broad set of best-in-class 3D printing platforms, software, a materials and technology partner ecosystem, innovative leadership, and global GTM infrastructure, in order to position itself to capture share in a significant and growing global marketplace, with a focus on manufacturing, which the Company views as having the largest and fastest growing total addressable market. The Company’s approximately 2,600 granted and pending additive technology patents to date have been used to create models, prototypes, manufacturing tools, and production parts for a multitude of industries including aerospace, automotive, transportation, healthcare, consumer products, dental, medical, fashion and education. Stratasys’ products and comprehensive solutions improve product quality, development time, cost, time-to-market and patient care. The Company’s 3D ecosystem of solutions and expertise includes 3D printers, materials, software, expert services, and on-demand parts production. The condensed consolidated interim financial information herein is unaudited; however, such information reflects all adjustments (consisting of normal, recurring adjustments), which are, in the opinion of management, necessary for a fair statement of results for the interim period. The condensed consolidated interim financial statements include the accounts of Stratasys Ltd. and its subsidiaries. All intercompany accounts and transactions, including profits from intercompany sales not yet realized outside the Company, have been eliminated in consolidation. The Company’s financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”), which require the Company to make estimates based on assumptions about current and, for some estimates, future economic and market conditions which affect reported amounts and related disclosures in its financial statements. Although the Company’s current estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from the Company’s expectations, which could materially affect its results of operations and financial position. In particular, a number of estimates have been and will continue to be affected by global events and other longer-term macroeconomic conditions, most prominently, the extent and speed at which inflation subsides, whether and when interest rates are reduced by central banks, whether and when tight credit conditions are loosened, whether capital markets continue to rise and whether global supply chains remain open. As a result, the accounting estimates and assumptions may change over time. Such changes could have an additional impact on the Company’s long-lived asset, goodwill and intangible asset valuations; and the allowance for expected credit losses. These consolidated financial statements reflect the financial statement effects based upon management’s estimates and assumptions utilizing the most currently available information.  In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these financial statements, the war in Israel is ongoing and continues to evolve. One of the Company’s global headquarters and one of its manufacturing facilities are located in Israel. As of the publication date of these financial statements, the Company's activities in Israel remain largely unaffected by the war. During the six months ended June 30, 2024, the impact of the war on the Company’s results of operations and financial condition was limited, but such impact may change, and could be significant, as a result of the continuation, escalation or expansion of the war. The Company continues to maintain business continuity plans backed by its inventory levels located outside of Israel. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of results that could be expected for the entire fiscal year. Certain financial information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. The reader is referred to the Company's audited consolidated financial statements and notes thereto for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 11, 2024 as part of the Company’s Annual Report on Form 20-F for such year.
Accounting Standards Update and Change in Accounting Principle	Note 2. New Accounting Pronouncements     Recently issued accounting pronouncements, not yet adopted In November 2023, the FASB issued ASU 2023-07 “Segment Reporting: Improvements to Reportable Segment Disclosures”. This guidance expands public entities’ segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment’s profit or loss and assets. Public entities with a single reportable segment are required to provide the new disclosures and all the disclosures required under ASC 280. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments are required to be applied retrospectively to all prior periods presented in an entity’s financial statements. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements related disclosures. In December 2023, the FASB issued ASU 2023-09 “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”. This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024 on a prospective basis, with the option to apply the standard retrospectively. Early adoption is permitted. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

v3.24.2.u1

Certain Transactions	6 Months Ended
	Jun. 30, 2024
Certain Transactions [Abstract]
Certain Transactions	Note 3. Certain Transactions   Covestro acquisition On April 3, 2023 (the “Covestro transaction date”), the Company completed the acquisition of the additive manufacturing materials business of Covestro AG. Covestro’s additive manufacturing business is expected to give the Company the ability to accelerate innovative developments in 3D printing materials and to thereby further grow adoption of its newest technologies. Also, the Company acquired an IP portfolio comprised of hundreds of patents and pending patents, including all of the SOMOS™ portfolio. The Covestro transaction is reflected in accordance with ASC Topic 805, “Business Combinations”. The assets acquisition transaction meets the definition of a business and was accounted for as a “Business Combinations” transaction, using the acquisition method of accounting with the Company as the acquirer. The following table summarizes the fair value of the consideration transferred to Covestro AG for the Covestro transaction: U.S. $ in thousands Cash payments $ 53,815  Issuance of ordinary shares to Covestro stockholders     5,202  Contingent consideration at estimated fair value 659  Other liability 868  Total consideration $ 60,544  The fair value of the ordinary shares issued was determined based on the closing market price of the Company's ordinary shares on the Covestro transaction date. In accordance with ASC Topic 805, the estimated contingent consideration as of the Covestro transaction date was included in the purchase price. The total contingent payments could amount to a maximum aggregate amount of up to €37 million. The payment will be settled through the issuance of ordinary shares. The estimated fair value of the contingent consideration is based on management’s assessment of whether, and at what level, the financial metrics will be achieved, and the present value factors associated with the timing of the payments. This fair value measurement is based on significant unobservable inputs in the market and thus represents a Level 3 measurement within the fair value hierarchy. Changes in the fair value of contingent consideration will be recorded in operating expenses. Refer to Note 9. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the Covestro transaction date. The estimated fair values are based on the information that was available as of April 3, 2023. The allocation of the purchase price to assets acquired and liabilities assumed is as follows: Allocation of Purchase Price U.S. $ in thousands Inventory $ 10,342  Fixed assets 7,064  Intangible assets 21,929  Other liabilities (605) Total identifiable net assets 38,730  Goodwill 21,814  Total consideration $ 60,544  The allocation of the PPA to net assets acquired and liabilities assumed resulted in the recognition of intangible assets related to developed technology, customer relationship, and trade name. These intangible assets have a useful life of 7 to 10 years. The fair value estimate of the customer relationship was determined using a variation of the income approach known as the “Multi-Period Excess Earnings Approach”. This valuation technique estimates the fair value of an asset based on market participants’ expectations of the cash flows the asset would generate over its remaining useful life. The net cash flows were discounted to present value. The fair value estimate of the developed technology and trade name, were estimated using the "Relief from royalty" method. This valuation technique estimates the fair value of the asset based on the hypothetical royalty payment that a licensee would be required to pay in exchange for use of the asset. Goodwill was recorded as the residual amount by which the purchase price exceeded the provisional fair value of the net assets acquired and is expected to be fully deductible for tax purposes. Goodwill consists primarily of expected synergies of combining operations, the acquired workforce, and growth opportunities, none of which qualify as separately identifiable intangible assets. Pro forma information giving effect to the acquisition has not been provided, as the results would not be material. During 2023, the Company completed several transactions, including acquisitions of an entity and additional assets, for a total consideration of $22 million. MakerBot and Ultimaker transaction ("Ultimaker") On August 31, 2022, Stratasys completed the merger of MakerBot (previously, a wholly-owned subsidiary) with Ultimaker, which together formed a new entity under the name Ultimaker. The Company accounts for its investment in the combined company Ultimaker according to the equity method in accordance with ASC Topic 323, as it has retained the ability to exercise significant influence but does not control the new entity. The Company recognized an equity method investment in a total amount of $105.6 million comprised of the assumed fair value of the MakerBot shares and additional amount invested in cash by the Company, representing a share of 46.5% in the new entity. During 2023, Ultimaker encountered difficulties in its business partially as a result of tighter competition and global market conditions. As a result, senior management at Ultimaker was replaced and the new management implemented a restructuring plan and additional steps to reduce cost and improve profitability. The Company considered such events as indicators of potential impairment and accordingly performed an impairment analysis for the investment in Ultimaker. Based on such valuation, the fair value of the investment was estimated below its carrying amount and such reduction in fair value was determined to be other than temporary. Accordingly the Company recorded an impairment charge in an amount of $13.9 million, which was recorded in share in losses of associated companies in the consolidated statements of operations and comprehensive loss. Management’s cash flow projections for the fair value of the investment in Ultimaker include significant judgments and assumptions relating to the cash flow projections, future growth and future profitability. Actual results could differ from those estimates, and such differences could be material and may result in other than temporary reduction in fair value, which could lead to additional impairments in the carrying value of the Ultimaker investment. On March 22, 2024, Ultimaker's shareholders agreed to provide it with additional funding of $8.0 million in cash, out of which $4.5 million was funded by the Company during the six months ended June 30, 2024. As of June 30, 2024 and December 31, 2023 the Company's equity investment in Ultimaker amounted to $72.2 million and $67.8 million, respectively, which represents the Company's investment in Ultimaker, net of the Company's share in Ultimaker's net losses for the respective periods in amounts of $0.1 million and $32.4 million, respectively. Other long-term investments In addition to the investment in Ultimaker, other investments included under Long-term investments represent investments in non-marketable equity securities and convertible notes of several companies without readily determinable fair value in which the Company does not have a controlling interest or significant influence. During the six months ended June 30, 2024 and during 2023, the Company invested a total of $5.4 million and $11.5 million, respectively, in non-marketable equity securities and convertible notes of several companies.

v3.24.2.u1

Revenues	6 Months Ended
	Jun. 30, 2024
Revenue Recognition [Abstract]
Revenues	Note 4. Revenues Disaggregation of Revenues The following table presents the Company’s revenues disaggregated by geographical region (based on the Company's customers' locations) and revenue type for the three and six months ended June 30, 2024 and 2023: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 (U.S. $ in thousands) (U.S. $ in thousands) Americas Systems $ 14,054  $ 28,975  $ 32,047  $ 50,161  Consumables 36,182  33,757  71,724  66,329  Service 33,252  39,463  66,525  75,785  Total Americas 83,488  102,195  170,296  192,275  EMEA Systems 9,800  12,054  19,523  23,456  Consumables 19,945  17,910  41,115  36,821  Service 7,308  6,920  14,888  14,487  Total EMEA 37,053  36,884  75,526  74,764  Asia Pacific Systems 5,125  7,284  10,294  15,148  Consumables 8,488  9,132  18,087  18,168  Service 3,887  4,256  7,888  8,773  Total Asia Pacific 17,500  20,672  36,269  42,089  Total Revenues $ 138,041  $ 159,751  $ 282,091  $ 309,128  The following table presents the Company’s revenues disaggregated based on the timing of revenue recognition (at a specific point in time or over the course of time) for the three and six months ended June 30, 2024 and 2023: Three Months Ended June 30, six months ended June 30, 2024 2024 2023 2024 2023 (U.S. $ in thousands) (U.S. $ in thousands) Revenues recognized in point in time from: Products $ 93,594  $ 109,112  $ 192,790  $ 210,083  Services 12,847  14,156  26,619  27,847  Total revenues recognized in point in time 106,441  123,268  219,409  237,930  Revenues recognized over time from: Services 31,600  36,483  62,682  71,198  Total revenues recognized over time 31,600  36,483  62,682  71,198  Total Revenues $ 138,041  $ 159,751  $ 282,091  $ 309,128  Contract Assets and Contract Liabilities Contract assets are recorded when the Company's right to consideration is conditioned on constraints other than the passage of time. The Company had no material contract assets as of June 30, 2024 and December 31, 2023. Contract liabilities include advance payments and billings in excess of revenue recognized, which are primarily related to advanced billings for service type warranty. Contract liabilities are presented under deferred revenue. The Company's deferred revenue as of June 30, 2024 and December 31, 2023 was as follows: June 30, December 31, 2024 2023 U.S. $ in thousands Deferred revenue * $ 69,794  $ 76,265  *Includes $18.9 million and $23.7 million under long-term deferred revenue in the Company's consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively. Revenue recognized in 2024 that was included in deferred revenue balance as of December 31, 2023 was $14.5 million and $33.1 million  for the three and six months ended June 30, 2024, respectively. Remaining Performance Obligations Remaining Performance Obligations (“RPO“) represent contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. As of June 30, 2024, the total RPO amounted to $98.3 million. The Company expects to recognize $68.0 million of this RPO during the next 12 months, $14.7 million over the subsequent 12 months and the remaining $15.6 million thereafter. Incremental Costs of Obtaining a Contract Sales commissions earned mainly by the Company’s sales agents are considered incremental costs of obtaining a contract with a customer, as the Company expects the benefit of those commissions to be longer than one year. The majority of the sales commissions are not subject to capitalization, as the commission expense is recognized as the related revenue is recognized. Sales commissions for initial contracts related to the service type warranty are deferred and then amortized on a straight-line basis over the expected customer relationship period if the Company expects to recover those costs. Amortization expense is included in selling, general and administrative expenses in the consolidated statements of operations. As of June 30, 2024 and December 31, 2023, the deferred commissions amounted to $10.3 million and $10.3 million, respectively.

v3.24.2.u1

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2024
Disclosure Text Block Supplement [Abstract]
Goodwill and Intangible Assets Disclosure	Note 6. Goodwill and Other Intangible Assets  Goodwill Changes in the carrying amount of the Company’s goodwill during the six months ended June 30, 2024 were as follows: U.S. $ in thousands Goodwill as of January 1, 2024 $ 100,051  Foreign currency translation adjustments (877) Goodwill as of June 30, 2024 $ 99,174  During the fourth quarter of 2023, the Company performed its annual impairment test for goodwill impairment. The Company performed a quantitative assessment for goodwill impairment for its Stratasys-Core reporting unit and concluded that the fair value of Stratasys-Core reporting unit exceeded its carrying amount by approximately 34%, with a carrying amount of goodwill assigned to this reporting unit in an amount of $100.0 million. When evaluating the fair value of Stratasys-Core reporting unit under the income approach, the Company used a discounted cash flow model which utilized Level 3 measures that represent unobservable inputs. Key assumptions used to determine the estimated fair value include: (a) internal cash flows forecasts for 4 years following the assessment date, including expected revenue growth, costs to produce, operating profit margins and estimated capital needs; (b) an estimated terminal value using a terminal year long- term future growth determined based on the growth prospects of the reporting unit; and (c) a discount rate which reflects the weighted average cost of capital adjusted for the relevant risk associated with the Stratasys-Core reporting unit operations and the uncertainty inherent in the Company's internally developed forecasts. In order to assess the reasonableness of its cash flow projections used for its goodwill impairment analysis, the Company compared the aggregate fair value of its reporting units to its market capitalization and calculated the implied control premium. The Company believes that its fair value assessment is reasonably supported by its calculated market capitalization. Actual results may differ from those assumed in the Company's valuation method. It is reasonably possible that the Company's assumptions described above could change in future periods. If any of these were to vary materially from the Company's plans, it may record impairment of goodwill allocated to this reporting unit in the future. Based on the Company’s assessment as of December 31, 2023, no goodwill was determined to be impaired. During the second quarter of 2024, the Company performed an analysis of the impact of recent events, including business and industry specific considerations, on the fair value of Stratasys-Core reporting unit. As part of this analysis the Company considered the changes in market capitalization and the sensitivity of estimates and assumptions used in the last annual impairment test as well as potential impacts of macro-economic pressure. The Company also analyzed the aggregate fair value of its reporting units compared to its market capitalization as part of its goodwill impairment test, in order to assess the reasonableness of the results of its cash flow projections used for its goodwill impairment analysis. The Company noted its market capitalization was below management’s assessment of the aggregate fair value of its reporting units. However, as of June 30, 2024, the Company’s market capitalization plus a reasonable control premium exceeded its book value. While management believes the goodwill of the reporting unit is currently not impaired, there can be no assurances that goodwill will not be impaired in future periods. The Company will continue to monitor the fair value of its Stratasys-Core reporting unit to determine whether events and changes in circumstances such as further deterioration in the business climate or operating results, significant decline in the Company's share price, changes in management’s business strategy or downward changes of the Company's cash flows projections, warrant further interim impairment testing. Other Intangible Assets Other intangible assets consisted of the following: June 30, 2024 December 31, 2023 Carrying Amount, net of Impairment Accumulated Amortization Net book value   Carrying Amount, net of Impairment Accumulated Amortization Net book value U.S. $ in thousands Developed technology $ 403,035  $ (309,542) $ 93,493  $ 403,180  $ (300,780) $ 102,400  Patents 20,975  (11,041) 9,934  19,396  (10,246) 9,150  Trademarks and trade names 22,161  (16,940) 5,221  22,286  (15,936) 6,350  Customer relationships 102,634  (94,821) 7,813  102,520  (92,639) 9,881  Capitalized software development costs 3,236  (3,236) —  4,367  (4,367) —  $ 552,041  $ (435,580) $ 116,461  $ 551,749  $ (423,968) $ 127,781  Amortization expenses relating to intangible assets for the three-month periods ended June 30, 2024 and 2023 were approximately $5.7 million and $7.1 million, respectively. Amortization expenses relating to intangible assets for the six-month periods ended June 30, 2024 and 2023 were approximately $12.6 million and $13.3 million, respectively. As of June 30, 2024, the estimated amortization expenses relating to intangible assets for each of the following future periods were as follows: Estimated amortization expenses (U.S. $ in thousands) Remaining 6 months of 2024 $ 11,245  2025 21,336 2026 21,247 2027 20,320 2028 16,290 2029 and thereafter 26,023 Total $ 116,461

v3.24.2.u1

Net Loss per Share	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Net loss per Share	Note 7. Net Loss Per Share The following table presents the numerator and denominator of the basic and diluted net loss per share computations for the three and six months ended June 30, 2024 and 2023: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 In thousands, except per share amounts In thousands, except per share amounts Numerator: Net loss for basic and diluted net loss per share $ (25,743) $ (38,615) $ (51,726) $ (60,839) Denominator: Weighted average shares - for basic and diluted net loss per share 70,746  68,648  70,367  68,107  Net loss per share Basic and diluted $ (0.36) $ (0.56) $ (0.74) $ (0.89)  The computation of diluted net loss per share excluded share awards of 5.5 million shares and 3.0 million million shares for the three months ended June 30, 2024 and 2023 respectively, because the inclusion of those shares would have had an anti-dilutive effect on the diluted net loss per share.  The computation of diluted net loss per share excluded share awards of 3.9 million shares and 3.3 million shares for the six months ended June 30, 2024 and 2023 respectively, because the inclusion of those shares would have had an anti-dilutive effect on the diluted net loss per share.

v3.24.2.u1

Fair Value Measurement	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurement	Note 9. Fair Value Measurements The following table summarizes the Company’s financial assets and liabilities that are carried at fair value on a recurring basis, in its consolidated balance sheets: June 30, 2024 December 31, 2023 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 (U.S. $ in thousands) Assets: Foreign exchange forward contracts not designated as hedging instruments $ —  $ 82  $ —  $ —  $ 164  $ —  Foreign exchange forward contracts designated as hedging instruments —  1,485  —  —  2,087  —  Convertible notes —  —  8,786  —  —  7,018  Marketable securities 828  1,994  —  —  Liabilities: Foreign exchange forward contracts not designated as hedging instruments —  (31) —  —  (51) —  Foreign exchange forward contracts designated as hedging instruments —  (47) —  —  (657) —  Contingent consideration* —  —  (18,371) —  —  (18,603) $ 828  $ 1,489  $ (9,585) $ 1,994  $ 1,543  $ (11,585) *Includes $6.5 million and $6.7 million under accrued expenses and other current liabilities in the Company's consolidated balance sheets as of June 30, 2024 and December 31, 2023, respectively. The Company's foreign exchange forward contracts are classified as Level 2, as they are not actively traded and are valued using pricing models that use observable market inputs, including interest rate curves and both forward and spot prices for currencies (Level 2 inputs). Contingent consideration represents liabilities recorded at fair value in connection with acquisitions, and thus represents a Level 3 measurement within the fair value hierarchy (refer to Note 3). Other financial instruments consist mainly of cash and cash equivalents, short-term deposits, current and non-current receivables, accounts payable and other current liabilities. The fair value of these financial instruments approximates their carrying values.

v3.24.2.u1

Derivatives and Hedging Activities	3 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Hedging Activities	Note 10. Derivative instruments and hedging activities Since the Company conducts its operations globally, it is exposed to global market risks and to the risk that its earnings, cash flows and equity could be adversely impacted by fluctuations in foreign currency exchange rates. The Company enters into transactions involving foreign currency exchange derivative financial instruments. The Company manages its foreign currency exposures on a consolidated basis, which allows the Company to net exposures and take advantage of any natural hedging. The transactions are designed to manage the Company’s net exposure to foreign currency exchange rates and to reduce the volatility of earnings and cash flows associated with changes in foreign currency exchange rates. The Company does not enter into derivative transactions for trading purposes. The Company is primarily exposed to foreign exchange risk with respect to recognized assets and liabilities and forecasted transactions denominated in the New Israeli Shekel (“NIS”), Euro, British Pound, Korean Won, Chinese Yuan and the Japanese Yen. The gains and losses on the hedging instruments partially offset losses and gains on the hedged items. Financial markets and currency volatility may limit the Company’s ability to hedge these exposures. These contracts mature through December 2024. The following table summarizes the consolidated balance sheets classification and fair values of the Company’s derivative instruments: Fair Value Notional Amount Balance sheet location June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 U.S. $ in thousands Assets derivatives -Foreign exchange contracts, not designated as hedging instruments Other current assets $ 82  $ 164  $ 35,581  $ 82,873  Assets derivatives -Foreign exchange contracts, designated as cash flow hedge Other current assets 1,485  2,087  54,152  51,830  Liability derivatives -Foreign exchange contracts, not designated as hedging instruments Accrued expenses and other current liabilities (31) (51) 47,237  21,168  Liability derivatives -Foreign exchange contracts, designated as cash flow hedge Accrued expenses and other current liabilities (47) (657) 13,066  74,054  $ 1,489  $ 1,543  $ 150,036  $ 229,925  Foreign exchange contracts not designated as hedging instruments As of June 30, 2024, the notional amounts of the Company’s outstanding exchange forward contracts, not designated as hedging instruments, were $82.8 million, and were used to reduce foreign currency exposures of the Euro, New Israeli Shekel (the "NIS"), British Pound, Japanese Yen, Korean Won and Chinese Yuan. With respect to such derivatives, a gain of $0.5 million and a gain of $1.6 million were recognized under financial expenses, net for the three-month periods ended June 30, 2024 and 2023, respectively and a gain of $1.8 million and a gain of $1.2 million million were recognized under financial expenses, net for the six-month periods ended June 30, 2024 and 2023, respectively. Such gains partially offset the revaluation losses of the balance sheet items which are also recognized under financial income (expenses), net. Cash Flow Hedging - Hedges of Forecasted Foreign Currency Payroll and other operating expenses As of June 30, 2024, the Company had in effect foreign exchange forward contracts, designated as cash flow hedges for accounting purposes, for the conversion of $27.3 million into NIS. The Company uses short-term cash flow hedge contracts to reduce its exposure to variability in expected future cash flows resulting mainly from payroll costs denominated in New Israeli Shekels. The changes in fair value of those contracts are included in the Company’s accumulated other comprehensive loss. Cash Flow Hedging - Hedges of Forecasted Foreign Currency Revenue The Company transacts business in U.S. Dollars and in various other currencies. The Company may use foreign exchange or forward contracts to hedge certain cash flow exposures resulting from changes in these foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities of up to twelve months. The Company enters into these foreign exchange contracts to hedge a portion of its forecasted foreign currency denominated revenue in the normal course of business, and accordingly, they are not speculative in nature. As of June 30, 2024, the Company had in effect foreign exchange forward contracts, designated as cash flow hedges for accounting purposes, for the conversion of €36.0 million into dollars.

v3.24.2.u1

Equity	6 Months Ended
	Jun. 30, 2024
Stockholders' Equity Note [Abstract]
Equity	Note 11. Equity a. Stock-based compensation plans Stock-based compensation expenses for equity-classified stock options, restricted share units (“RSUs”) and performance-based restricted share units (”PSUs”) were allocated as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 U.S $ in thousands U.S $ in thousands Cost of revenues $ 1,010  $ 999  $ 1,962  $ 1,931  Research and development, net 2,120  1,867  4,251  3,956  Selling, general and administrative 4,216  5,156  9,782  10,376  Total stock-based compensation expenses $ 7,346  $ 8,022  $ 15,995  $ 16,263  A summary of the Company’s stock option activity for the six months ended June 30, 2024 is as follows: Number of Options Weighted Average Exercise Price Options outstanding as of January 1, 2024 1,360,652  20.67  Granted —  —  Exercised (12,413) 12.30  Forfeited (54,569) 24.30  Options outstanding as of June 30, 2024 1,293,670  20.60  Options exercisable as of June 30, 2024 1,014,148  21.80  As of June 30, 2024, the unrecognized compensation cost of $0.3 million related to all unvested, equity-classified stock options is expected to be recognized as an expense over a weighted-average period of 1.56 years. A summary of the Company’s RSUs and PSUs activity for the six months ended June 30, 2024 is as follows: Number of RSUs and PSUs Weighted Average Grant Date Fair Value Unvested as of January 1, 2024 3,842,232  17.95  Granted 1,867,931  11.77  Vested (1,020,493) 19.12  Forfeited (213,697) 19.14  Unvested as of June 30, 2024 4,475,973  18.83  The fair value of RSUs and PSUs is determined based on the quoted price of the Company’s ordinary shares on the date of the grant. As of June 30, 2024, the unrecognized compensation cost of $55.7 million related to all unvested, equity-classified RSUs and PSUs is expected to be recognized as expense over a weighted-average period of 2.79 years. b. Accumulated other comprehensive loss The following tables present the changes in the components of accumulated other comprehensive income (loss), net of taxes, for the six months ended June 30, 2024 and 2023, respectively: Six Months Ended June 30, 2024 Net Unrealized Gain (Loss) on Cash Flow Hedges Foreign Currency Translation Adjustments Total U.S. $ in thousands Balance as of January 1, 2024 $ 1,790  $ (8,869) $ (7,079) Other comprehensive income (loss) before reclassifications 1,459  (2,210) (751) Amounts reclassified from accumulated other comprehensive loss (1,303) —  (1,303) Other comprehensive loss 156  (2,210) (2,054) Balance as of June 30, 2024 $ 1,946  $ (11,079) $ (9,133) Six Months Ended June 30, 2023 Net Unrealized Gain (Loss) on Cash Flow Hedges Foreign Currency Translation Adjustments Total U.S. $ in thousands Balance as of January 1, 2023 $ (299) $ (12,519) $ (12,818) Other comprehensive income before reclassifications (2,708) 1,834  (874) Amounts reclassified from accumulated other comprehensive loss 1,021  —  1,021  Other comprehensive income (1,687) 1,834  147  Balance as of June 30, 2023 $ (1,986) $ (10,685) $ (12,671)

v3.24.2.u1

Certain Transactions (Tables)	6 Months Ended
	Jun. 30, 2024
Certain Transactions [Abstract]
Schedule of preliminary allocation of the purchase price to assets acquired and liabilities	U.S. $ in thousands Cash payments $ 53,815  Issuance of ordinary shares to Covestro stockholders     5,202  Contingent consideration at estimated fair value 659  Other liability 868  Total consideration $ 60,544

v3.24.2.u1

Revenues (Tables)	6 Months Ended
	Jun. 30, 2024
Revenue Recognition [Abstract]
Schedule of disaggregation of revenues	The following table presents the Company’s revenues disaggregated by geographical region (based on the Company's customers' locations) and revenue type for the three and six months ended June 30, 2024 and 2023: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 (U.S. $ in thousands) (U.S. $ in thousands) Americas Systems $ 14,054  $ 28,975  $ 32,047  $ 50,161  Consumables 36,182  33,757  71,724  66,329  Service 33,252  39,463  66,525  75,785  Total Americas 83,488  102,195  170,296  192,275  EMEA Systems 9,800  12,054  19,523  23,456  Consumables 19,945  17,910  41,115  36,821  Service 7,308  6,920  14,888  14,487  Total EMEA 37,053  36,884  75,526  74,764  Asia Pacific Systems 5,125  7,284  10,294  15,148  Consumables 8,488  9,132  18,087  18,168  Service 3,887  4,256  7,888  8,773  Total Asia Pacific 17,500  20,672  36,269  42,089  Total Revenues $ 138,041  $ 159,751  $ 282,091  $ 309,128
Schedule of changes in deferred revenue	Three Months Ended June 30, six months ended June 30, 2024 2024 2023 2024 2023 (U.S. $ in thousands) (U.S. $ in thousands) Revenues recognized in point in time from: Products $ 93,594  $ 109,112  $ 192,790  $ 210,083  Services 12,847  14,156  26,619  27,847  Total revenues recognized in point in time 106,441  123,268  219,409  237,930  Revenues recognized over time from: Services 31,600  36,483  62,682  71,198  Total revenues recognized over time 31,600  36,483  62,682  71,198  Total Revenues $ 138,041  $ 159,751  $ 282,091  $ 309,128

v3.24.2.u1

Inventories (Tables)	6 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Schedule of inventories	Inventories consisted of the following: June 30, 2024 December 31, 2023 U.S. $ in thousands Finished goods $ 95,670  $ 86,908  Work-in-process 9,870  9,871  Raw materials 90,965  96,197  $ 196,505  $ 192,976

v3.24.2.u1

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure Text Block Supplement [Abstract]
Schedule of other intangible assets	Other intangible assets consisted of the following: June 30, 2024 December 31, 2023 Carrying Amount, net of Impairment Accumulated Amortization Net book value   Carrying Amount, net of Impairment Accumulated Amortization Net book value U.S. $ in thousands Developed technology $ 403,035  $ (309,542) $ 93,493  $ 403,180  $ (300,780) $ 102,400  Patents 20,975  (11,041) 9,934  19,396  (10,246) 9,150  Trademarks and trade names 22,161  (16,940) 5,221  22,286  (15,936) 6,350  Customer relationships 102,634  (94,821) 7,813  102,520  (92,639) 9,881  Capitalized software development costs 3,236  (3,236) —  4,367  (4,367) —  $ 552,041  $ (435,580) $ 116,461  $ 551,749  $ (423,968) $ 127,781
Schedule of estimated amortization expense relating to intangible assets	As of June 30, 2024, the estimated amortization expenses relating to intangible assets for each of the following future periods were as follows: Estimated amortization expenses (U.S. $ in thousands) Remaining 6 months of 2024 $ 11,245  2025 21,336 2026 21,247 2027 20,320 2028 16,290 2029 and thereafter 26,023 Total $ 116,461

v3.24.2.u1

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of calculation of basic and diluted net loss per share	The following table presents the numerator and denominator of the basic and diluted net loss per share computations for the three and six months ended June 30, 2024 and 2023: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 In thousands, except per share amounts In thousands, except per share amounts Numerator: Net loss for basic and diluted net loss per share $ (25,743) $ (38,615) $ (51,726) $ (60,839) Denominator: Weighted average shares - for basic and diluted net loss per share 70,746  68,648  70,367  68,107  Net loss per share Basic and diluted $ (0.36) $ (0.56) $ (0.74) $ (0.89)

v3.24.2.u1

Derivatives and Hedging Activities (Tables)	6 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of balance sheet classification and fair values of derivative instruments	The following table summarizes the consolidated balance sheets classification and fair values of the Company’s derivative instruments: Fair Value Notional Amount Balance sheet location June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 U.S. $ in thousands Assets derivatives -Foreign exchange contracts, not designated as hedging instruments Other current assets $ 82  $ 164  $ 35,581  $ 82,873  Assets derivatives -Foreign exchange contracts, designated as cash flow hedge Other current assets 1,485  2,087  54,152  51,830  Liability derivatives -Foreign exchange contracts, not designated as hedging instruments Accrued expenses and other current liabilities (31) (51) 47,237  21,168  Liability derivatives -Foreign exchange contracts, designated as cash flow hedge Accrued expenses and other current liabilities (47) (657) 13,066  74,054  $ 1,489  $ 1,543  $ 150,036  $ 229,925

v3.24.2.u1

Equity (Tables)	6 Months Ended
	Jun. 30, 2024
Stockholders' Equity Note [Abstract]
Schedule of stock-based compensation expense	Stock-based compensation expenses for equity-classified stock options, restricted share units (“RSUs”) and performance-based restricted share units (”PSUs”) were allocated as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 U.S $ in thousands U.S $ in thousands Cost of revenues $ 1,010  $ 999  $ 1,962  $ 1,931  Research and development, net 2,120  1,867  4,251  3,956  Selling, general and administrative 4,216  5,156  9,782  10,376  Total stock-based compensation expenses $ 7,346  $ 8,022  $ 15,995  $ 16,263
Schedule of stock option activity	A summary of the Company’s stock option activity for the six months ended June 30, 2024 is as follows: Number of Options Weighted Average Exercise Price Options outstanding as of January 1, 2024 1,360,652  20.67  Granted —  —  Exercised (12,413) 12.30  Forfeited (54,569) 24.30  Options outstanding as of June 30, 2024 1,293,670  20.60  Options exercisable as of June 30, 2024 1,014,148  21.80
Schedule of RSUs and PSUs activity	A summary of the Company’s RSUs and PSUs activity for the six months ended June 30, 2024 is as follows: Number of RSUs and PSUs Weighted Average Grant Date Fair Value Unvested as of January 1, 2024 3,842,232  17.95  Granted 1,867,931  11.77  Vested (1,020,493) 19.12  Forfeited (213,697) 19.14  Unvested as of June 30, 2024 4,475,973  18.83
Schedule of accumulated other comprehensive loss	The following tables present the changes in the components of accumulated other comprehensive income (loss), net of taxes, for the six months ended June 30, 2024 and 2023, respectively: Six Months Ended June 30, 2024 Net Unrealized Gain (Loss) on Cash Flow Hedges Foreign Currency Translation Adjustments Total U.S. $ in thousands Balance as of January 1, 2024 $ 1,790  $ (8,869) $ (7,079) Other comprehensive income (loss) before reclassifications 1,459  (2,210) (751) Amounts reclassified from accumulated other comprehensive loss (1,303) —  (1,303) Other comprehensive loss 156  (2,210) (2,054) Balance as of June 30, 2024 $ 1,946  $ (11,079) $ (9,133) Six Months Ended June 30, 2023 Net Unrealized Gain (Loss) on Cash Flow Hedges Foreign Currency Translation Adjustments Total U.S. $ in thousands Balance as of January 1, 2023 $ (299) $ (12,519) $ (12,818) Other comprehensive income before reclassifications (2,708) 1,834  (874) Amounts reclassified from accumulated other comprehensive loss 1,021  —  1,021  Other comprehensive income (1,687) 1,834  147  Balance as of June 30, 2023 $ (1,986) $ (10,685) $ (12,671)

v3.24.2.u1

Certain Transactions (Tables)	6 Months Ended
	Jun. 30, 2024
Certain Transactions [Abstract]
Schedule of preliminary allocation of the purchase price to assets acquired and liabilities	U.S. $ in thousands Cash payments $ 53,815  Issuance of ordinary shares to Covestro stockholders     5,202  Contingent consideration at estimated fair value 659  Other liability 868  Total consideration $ 60,544

v3.24.2.u1

Revenues (Tables)	6 Months Ended
	Jun. 30, 2024
Revenue Recognition [Abstract]
Schedule of disaggregation of revenues	The following table presents the Company’s revenues disaggregated by geographical region (based on the Company's customers' locations) and revenue type for the three and six months ended June 30, 2024 and 2023: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 (U.S. $ in thousands) (U.S. $ in thousands) Americas Systems $ 14,054  $ 28,975  $ 32,047  $ 50,161  Consumables 36,182  33,757  71,724  66,329  Service 33,252  39,463  66,525  75,785  Total Americas 83,488  102,195  170,296  192,275  EMEA Systems 9,800  12,054  19,523  23,456  Consumables 19,945  17,910  41,115  36,821  Service 7,308  6,920  14,888  14,487  Total EMEA 37,053  36,884  75,526  74,764  Asia Pacific Systems 5,125  7,284  10,294  15,148  Consumables 8,488  9,132  18,087  18,168  Service 3,887  4,256  7,888  8,773  Total Asia Pacific 17,500  20,672  36,269  42,089  Total Revenues $ 138,041  $ 159,751  $ 282,091  $ 309,128
Schedule of changes in deferred revenue	Three Months Ended June 30, six months ended June 30, 2024 2024 2023 2024 2023 (U.S. $ in thousands) (U.S. $ in thousands) Revenues recognized in point in time from: Products $ 93,594  $ 109,112  $ 192,790  $ 210,083  Services 12,847  14,156  26,619  27,847  Total revenues recognized in point in time 106,441  123,268  219,409  237,930  Revenues recognized over time from: Services 31,600  36,483  62,682  71,198  Total revenues recognized over time 31,600  36,483  62,682  71,198  Total Revenues $ 138,041  $ 159,751  $ 282,091  $ 309,128

v3.24.2.u1

Inventories (Tables)	6 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Schedule of inventories	Inventories consisted of the following: June 30, 2024 December 31, 2023 U.S. $ in thousands Finished goods $ 95,670  $ 86,908  Work-in-process 9,870  9,871  Raw materials 90,965  96,197  $ 196,505  $ 192,976

v3.24.2.u1

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Disclosure Text Block Supplement [Abstract]
Schedule of changes in the carrying amount of goodwill	Changes in the carrying amount of the Company’s goodwill during the six months ended June 30, 2024 were as follows: U.S. $ in thousands Goodwill as of January 1, 2024 $ 100,051  Foreign currency translation adjustments (877) Goodwill as of June 30, 2024 $ 99,174
Schedule of other intangible assets	Other intangible assets consisted of the following: June 30, 2024 December 31, 2023 Carrying Amount, net of Impairment Accumulated Amortization Net book value   Carrying Amount, net of Impairment Accumulated Amortization Net book value U.S. $ in thousands Developed technology $ 403,035  $ (309,542) $ 93,493  $ 403,180  $ (300,780) $ 102,400  Patents 20,975  (11,041) 9,934  19,396  (10,246) 9,150  Trademarks and trade names 22,161  (16,940) 5,221  22,286  (15,936) 6,350  Customer relationships 102,634  (94,821) 7,813  102,520  (92,639) 9,881  Capitalized software development costs 3,236  (3,236) —  4,367  (4,367) —  $ 552,041  $ (435,580) $ 116,461  $ 551,749  $ (423,968) $ 127,781
Schedule of estimated amortization expense relating to intangible assets	As of June 30, 2024, the estimated amortization expenses relating to intangible assets for each of the following future periods were as follows: Estimated amortization expenses (U.S. $ in thousands) Remaining 6 months of 2024 $ 11,245  2025 21,336 2026 21,247 2027 20,320 2028 16,290 2029 and thereafter 26,023 Total $ 116,461

v3.24.2.u1

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of calculation of basic and diluted net loss per share	The following table presents the numerator and denominator of the basic and diluted net loss per share computations for the three and six months ended June 30, 2024 and 2023: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 In thousands, except per share amounts In thousands, except per share amounts Numerator: Net loss for basic and diluted net loss per share $ (25,743) $ (38,615) $ (51,726) $ (60,839) Denominator: Weighted average shares - for basic and diluted net loss per share 70,746  68,648  70,367  68,107  Net loss per share Basic and diluted $ (0.36) $ (0.56) $ (0.74) $ (0.89)

v3.24.2.u1

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of book value of MakerBot's net assets	The following table summarizes the Company’s financial assets and liabilities that are carried at fair value on a recurring basis, in its consolidated balance sheets: June 30, 2024 December 31, 2023 Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 (U.S. $ in thousands) Assets: Foreign exchange forward contracts not designated as hedging instruments $ —  $ 82  $ —  $ —  $ 164  $ —  Foreign exchange forward contracts designated as hedging instruments —  1,485  —  —  2,087  —  Convertible notes —  —  8,786  —  —  7,018  Marketable securities 828  1,994  —  —  Liabilities: Foreign exchange forward contracts not designated as hedging instruments —  (31) —  —  (51) —  Foreign exchange forward contracts designated as hedging instruments —  (47) —  —  (657) —  Contingent consideration* —  —  (18,371) —  —  (18,603) $ 828  $ 1,489  $ (9,585) $ 1,994  $ 1,543  $ (11,585)

v3.24.2.u1

Derivatives and Hedging Activities (Tables)	6 Months Ended
	Jun. 30, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of balance sheet classification and fair values of derivative instruments	The following table summarizes the consolidated balance sheets classification and fair values of the Company’s derivative instruments: Fair Value Notional Amount Balance sheet location June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 U.S. $ in thousands Assets derivatives -Foreign exchange contracts, not designated as hedging instruments Other current assets $ 82  $ 164  $ 35,581  $ 82,873  Assets derivatives -Foreign exchange contracts, designated as cash flow hedge Other current assets 1,485  2,087  54,152  51,830  Liability derivatives -Foreign exchange contracts, not designated as hedging instruments Accrued expenses and other current liabilities (31) (51) 47,237  21,168  Liability derivatives -Foreign exchange contracts, designated as cash flow hedge Accrued expenses and other current liabilities (47) (657) 13,066  74,054  $ 1,489  $ 1,543  $ 150,036  $ 229,925

v3.24.2.u1

Equity (Tables)	6 Months Ended
	Jun. 30, 2024
Stockholders' Equity Note [Abstract]
Schedule of stock-based compensation expense	Stock-based compensation expenses for equity-classified stock options, restricted share units (“RSUs”) and performance-based restricted share units (”PSUs”) were allocated as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 U.S $ in thousands U.S $ in thousands Cost of revenues $ 1,010  $ 999  $ 1,962  $ 1,931  Research and development, net 2,120  1,867  4,251  3,956  Selling, general and administrative 4,216  5,156  9,782  10,376  Total stock-based compensation expenses $ 7,346  $ 8,022  $ 15,995  $ 16,263
Schedule of stock option activity	A summary of the Company’s stock option activity for the six months ended June 30, 2024 is as follows: Number of Options Weighted Average Exercise Price Options outstanding as of January 1, 2024 1,360,652  20.67  Granted —  —  Exercised (12,413) 12.30  Forfeited (54,569) 24.30  Options outstanding as of June 30, 2024 1,293,670  20.60  Options exercisable as of June 30, 2024 1,014,148  21.80
Schedule of RSUs and PSUs activity	A summary of the Company’s RSUs and PSUs activity for the six months ended June 30, 2024 is as follows: Number of RSUs and PSUs Weighted Average Grant Date Fair Value Unvested as of January 1, 2024 3,842,232  17.95  Granted 1,867,931  11.77  Vested (1,020,493) 19.12  Forfeited (213,697) 19.14  Unvested as of June 30, 2024 4,475,973  18.83
Schedule of accumulated other comprehensive loss	The following tables present the changes in the components of accumulated other comprehensive income (loss), net of taxes, for the six months ended June 30, 2024 and 2023, respectively: Six Months Ended June 30, 2024 Net Unrealized Gain (Loss) on Cash Flow Hedges Foreign Currency Translation Adjustments Total U.S. $ in thousands Balance as of January 1, 2024 $ 1,790  $ (8,869) $ (7,079) Other comprehensive income (loss) before reclassifications 1,459  (2,210) (751) Amounts reclassified from accumulated other comprehensive loss (1,303) —  (1,303) Other comprehensive loss 156  (2,210) (2,054) Balance as of June 30, 2024 $ 1,946  $ (11,079) $ (9,133) Six Months Ended June 30, 2023 Net Unrealized Gain (Loss) on Cash Flow Hedges Foreign Currency Translation Adjustments Total U.S. $ in thousands Balance as of January 1, 2023 $ (299) $ (12,519) $ (12,818) Other comprehensive income before reclassifications (2,708) 1,834  (874) Amounts reclassified from accumulated other comprehensive loss 1,021  —  1,021  Other comprehensive income (1,687) 1,834  147  Balance as of June 30, 2023 $ (1,986) $ (10,685) $ (12,671)

v3.24.2.u1

Certain Transactions - Consideration (Details)	6 Months Ended
	Jun. 30, 2024 USD ($)
Certain Transactions [Abstract]
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed	$ 53,815,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	5,202,000
Business Combination, Consideration Transferred, Other	659,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other.1	868,000
Total consideration for 55% holding	$ 60,544,000

v3.24.2.u1

Certain Transactions - Purchase Price Allocation (Details)	6 Months Ended
	Jun. 30, 2024 USD ($)
Restructuring and Related Activities [Abstract]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	$ 10,342,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets	7,064,000
Intangible assets	21,929,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other_MB	(605,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	38,730,000
Goodwill	21,814,000
Total consideration for 55% holding	$ 60,544,000

v3.24.2.u1

Revenues (Details) - Schedule of disaggregated by geographical region - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Americas
Total Revenues	$ 138,041	$ 159,751	$ 282,091	$ 309,128
Total Americas [Member]
Americas
Total Revenues	83,488	102,195	170,296	192,275
Total EMEA [Member]
Americas
Total Revenues	37,053	36,884	75,526	74,764
Total Asia Pacific [Member]
Americas
Total Revenues	17,500	20,672	36,269	42,089
Systems [Member] | Total Americas [Member]
Americas
Total Revenues	14,054	28,975	32,047	50,161
Systems [Member] | Total EMEA [Member]
Americas
Total Revenues	9,800	12,054	19,523	23,456
Systems [Member] | Total Asia Pacific [Member]
Americas
Total Revenues	5,125	7,284	10,294	15,148
Consumables [Member] | Total Americas [Member]
Americas
Total Revenues	36,182	33,757	71,724	66,329
Consumables [Member] | Total EMEA [Member]
Americas
Total Revenues	19,945	17,910	41,115	36,821
Consumables [Member] | Total Asia Pacific [Member]
Americas
Total Revenues	8,488	9,132	18,087	18,168
Service [Member]
Americas
Total Revenues	44,447	50,639	89,301	99,045
Service [Member] | Total Americas [Member]
Americas
Total Revenues	33,252	39,463	66,525	75,785
Service [Member] | Total EMEA [Member]
Americas
Total Revenues	7,308	6,920	14,888	14,487
Service [Member] | Total Asia Pacific [Member]
Americas
Total Revenues	$ 3,887	$ 4,256	$ 7,888	$ 8,773

v3.24.2.u1

Revenues (Details) - Schedule of disaggregation of revenues - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	$ 138,041	$ 159,751	$ 282,091	$ 309,128
Total revenues recognized in point in time [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	106,441	123,268	219,409	237,930
Total revenues recognized over time [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	31,600	36,483	62,682	71,198
Products [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	93,594	109,112	192,790	210,083
Products [Member] | Total revenues recognized in point in time [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	93,594	109,112	192,790	210,083
Services [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	44,447	50,639	89,301	99,045
Services [Member] | Total revenues recognized in point in time [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	12,847	14,156	26,619	27,847
Services [Member] | Total revenues recognized over time [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	$ 31,600	$ 36,483	$ 62,682	$ 71,198

v3.24.2.u1

Revenues (Details) - Schedule of changes in deferred revenue - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Schedule Of Changes In Deferred Revenue Abstract
Deferred revenue	$ 69,794,000	$ 69,794,000		$ 76,265,000
Deferred Long-Term Liability Charges	18,900,000	18,900,000	$ 23,700,000
Revenue recognized	$ 14,500,000	$ 33,100,000

v3.24.2.u1

Revenues - Narrative (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Dec. 31, 2023
Revenue Recognition [Abstract]
Deferred Long-Term Liability Charges	$ 18,900,000	$ 18,900,000	$ 23,700,000
Revenue recognized	14,500,000	33,100,000
Remaining performance obligations	98,300,000	98,300,000
Expected remaining performance obligations recognized during next 12 months	68,000,000.0	68,000,000.0
Expected remaining performance obligations recognized subsequent to next 12 months and thereafter	14,700,000	14,700,000
Expected remaining performance obligations recognized remainder thereafter	15,600,000	15,600,000
Deferred sales commissions	$ 10,300,000	$ 10,300,000	$ 10,300,000

v3.24.2.u1

Inventories (Details) - Schedule of inventories - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule Of Inventories Abstract
Finished goods	$ 95,670	$ 86,908
Raw materials	9,870	9,871
Work-in-process	90,965	96,197
Total inventory	$ 196,505	$ 192,976

v3.24.2.u1

Goodwill and Other Intangible Assets (Details) - Schedule of changes in the carrying amount of goodwill $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Balance at beginning	$ 100,051
Balance at ending	99,174
Goodwill
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Balance at beginning	100,051
Currency translation adjustments	(877)
Balance at ending	$ 99,174

v3.24.2.u1

Goodwill and Other Intangible Assets (Details) - Schedule of other intangible assets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Carrying Amount, Net of Impairment	$ 552,041	$ 551,749
Accumulated Amortization	(435,580)	(423,968)
Other intangible assets, net	116,461	127,781
Developed technology [Member]
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Carrying Amount, Net of Impairment	403,035	403,180
Accumulated Amortization	(309,542)	(300,780)
Other intangible assets, net	93,493	102,400
Patents [Member]
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Carrying Amount, Net of Impairment	20,975	19,396
Accumulated Amortization	(11,041)	(10,246)
Other intangible assets, net	9,934	9,150
Trademarks and trade names [Member]
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Carrying Amount, Net of Impairment	22,161	22,286
Accumulated Amortization	(16,940)	(15,936)
Other intangible assets, net	5,221	6,350
Customer relationships [Member]
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Carrying Amount, Net of Impairment	102,634	102,520
Accumulated Amortization	(94,821)	(92,639)
Other intangible assets, net	7,813	9,881
Capitalized software development costs [Member]
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Carrying Amount, Net of Impairment	3,236	4,367
Accumulated Amortization	(3,236)	(4,367)
Other intangible assets, net	$ 0	$ 0

v3.24.2.u1

Goodwill and Other Intangible Assets (Details) - Narrative - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule Of Changes In The Carrying Amount Of Goodwill Abstract
Amortization of intangible assets	$ 5,700,000	$ 7,100,000	$ 12,600,000	$ 13,300,000

v3.24.2.u1

Goodwill and Other Intangible Assets (Details) - Estimated Amortization Expense $ in Thousands	Jun. 30, 2024 USD ($)
Schedule Of Changes In The Carrying Amount Of Goodwill Abstract
2024	$ 11,245
2025	21,336
2026	21,247
2027	20,320
2028	16,290
2029 and thereafter	26,023
Net Book Value	$ 116,461

v3.24.2.u1

Net Loss per Share (Details) - Schedule of calculation of basic and diluted net loss per share - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Numerator:
Net loss attributable to Stratasys Ltd. for basic and diluted net loss per share	$ (25,743)	$ (38,615)	$ (51,726)	$ (60,839)
Denominator:
Weighted average shares – denominator for basic and diluted net loss per share	70,746,000	68,648,000	70,367,000	68,107,000
Earnings Per Share, Basic	$ (0.36)	$ (0.56)	$ (0.74)	$ (0.89)

v3.24.2.u1

Net Loss per Share - Narrative (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Anti-dilutive shares, excluded from computation of diluted net loss per share	5,500,000	3,000,000	3,900,000	3,300,000

v3.24.2.u1

Income Taxes - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Tax Disclosure [Abstract]
Current Income Tax Expense (Benefit)	$ 800,000	$ 700,000	$ 1,500,000	$ 4,500,000

v3.24.2.u1

Fair Value Measurement (Details) - Schedule of financial assets and liabilities that are carried at fair value on a recurring basis - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Liabilities:
Foreign exchange forward contracts fair value	$ 1,489	$ 1,543
Accounts Payable and Accrued Liabilities, Fair Value Disclosure	6,500	6,700
Fair Value, Inputs, Level 1
Assets:
Marketable Securities	828	1,994
Level 2 [Member]
Assets:
Foreign exchange forward contracts not designated as hedging instruments	82	164
Foreign exchange forward contracts designated as hedging instruments	1,485	2,087
Liabilities:
Foreign exchange forward contracts not designated as hedging instruments	(31)	(51)
Foreign exchange forward contracts designated as hedging instruments	(47)	(657)
Foreign exchange forward contracts fair value	1,489	1,543
Level 3 [Member]
Assets:
Convertible Debt, Fair Value Disclosures	8,786	7,018
Liabilities:
Contingent consideration	(18,371)	(18,603)
Schedule Of Fair Value Measurements Are Estimated Utilizing Level3 Inputs Abstract	$ 9,585	$ 11,585

v3.24.2.u1

Fair Value Measurement (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Accounts Payable and Accrued Liabilities, Fair Value Disclosure	$ 6,500	$ 6,700

v3.24.2.u1

Derivatives and Hedging Activities (Details) - Schedule of balance sheet classification and fair values of derivative instruments € in Thousands, $ in Thousands	Jun. 30, 2024 USD ($)	Jun. 30, 2024 EUR (€)	Dec. 31, 2023 USD ($)
Derivatives, Fair Value [Line Items]
Notional amount of derivative asset	$ 82,800	€ 36,000
Fair value	1,489		$ 1,543
Notional amount	150,036		229,925
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other current assets [Member]
Derivatives, Fair Value [Line Items]
Fair value derivative asset	82		164
Notional amount of derivative asset	35,581		82,873
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses and other current liabilities [Member]
Derivatives, Fair Value [Line Items]
Fair value derivative liability	(31)		(51)
Notional amount of derivative liability	47,237		21,168
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other current assets [Member] | Cash Flow Hedge [Member]
Derivatives, Fair Value [Line Items]
Notional amount of derivative asset			51,830
Fair value derivative asset	1,485		2,087
Notional amount of derivative asset	54,152
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses and other current liabilities [Member] | Cash Flow Hedge [Member]
Derivatives, Fair Value [Line Items]
Notional amount of derivative asset			657
Fair value derivative liability	(47)
Notional amount of derivative liability	$ 13,066		$ 74,054

v3.24.2.u1

Derivatives and Hedging Activities (Details) - Jun. 30, 2024 € in Thousands, $ in Thousands	USD ($)	EUR (€)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Notional amount of derivative asset	$ 82,800	€ 36,000

v3.24.2.u1

Equity (Details) - Schedule of stock-based compensation expense - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expenses	$ 7,346	$ 8,022	$ 15,995	$ 16,263
Cost of revenues [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expenses	1,010	999	1,962	1,931
Research and Development, Net [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expenses	2,120	1,867	4,251	3,956
Selling, General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expenses	$ 4,216	$ 5,156	$ 9,782	$ 10,376

v3.24.2.u1

Equity (Details) - Schedule of stock option activity	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Schedule Of Stock Option Activity Abstract
Options outstanding, Number of Options | shares	1,360,652
Options outstanding, Weighted Average Exercise Price | $ / shares	$ 20.67
Granted, Number of Options | shares	0
Granted, Weighted Average Exercise Price | $ / shares	$ 0
Exercised, Number of Options | shares	(12,413)
Exercised, Weighted Average Exercise Price | $ / shares	$ 12.30
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period | shares	(54,569)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | $ / shares	$ 24.30
Options outstanding, Number of Options | shares	1,293,670
Options outstanding, Weighted Average Exercise Price | $ / shares	$ 20.60
Options exercisable, Number of Options | shares	1,014,148
Options exercisable, Weighted Average Exercise Price | $ / shares	$ 21.80

v3.24.2.u1

Equity (Details) - Schedule of RSUs and PSUs activity - $ / shares	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Equity (Details) - Schedule of stock options outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	(54,569)
Restricted And Phantom Share Units Member
Equity (Details) - Schedule of stock options outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number	4,475,973	3,842,232
Granted, Number of RSUs and PSUs	1,867,931
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period	1,020,493
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	(213,697)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 18.83	$ 17.95
Granted, Weighted Average Grant Date Fair Value	11.77
Vested, Weighted Average Grant Date Fair Value	19.12
Forfeited, Weighted Average Grant Date Fair Value	$ 19.14

v3.24.2.u1

Equity (Details) - Schedule of accumulated other comprehensive loss - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ (7,079,000)	$ (12,818,000)
Other comprehensive loss before reclassifications	(751,000)	(874,000)
Amounts reclassified from accumulated other comprehensive loss	(1,303,000)	1,021,000
Other comprehensive income (loss)	(2,054,000)	147,000
Balance	(9,133,000)	(12,671,000)
Net unrealized gain (loss) on cash flow hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	1,790,000	(299,000)
Other comprehensive loss before reclassifications	1,459,000	(2,708,000)
Amounts reclassified from accumulated other comprehensive loss	(1,303,000)	1,021,000
Other comprehensive income (loss)	156,000	(1,687,000)
Balance	1,946,000	(1,986,000)
Foreign currency translation adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(8,869,000)	(12,519,000)
Other comprehensive loss before reclassifications	(2,210,000)	1,834,000
Amounts reclassified from accumulated other comprehensive loss	0	0
Other comprehensive income (loss)	(2,210,000)	1,834,000
Balance	$ (11,079,000)	$ (10,685,000)

v3.24.2.u1

Equity (Details)	6 Months Ended
	Jun. 30, 2024 USD ($)
Equity (Details) [Line Items]
Unrecognized compensation cost (in Dollars)	$ 55,700,000
Employee Stock Option [Member]
Equity (Details) [Line Items]
Weighted average period over which unrecognized compensation cost will be recognized	1 year 6 months 21 days
Unrecognized compensation cost (in Dollars)	$ 300,000
Restricted Stock Units (RSUs)
Equity (Details) [Line Items]
Weighted average period over which unrecognized compensation cost will be recognized	2 years 9 months 14 days

v3.24.2.u1

Certain Transactions - Consideration (Details)	6 Months Ended
	Jun. 30, 2024 USD ($)
Certain Transactions [Abstract]
Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed	$ 53,815,000
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable	5,202,000
Business Combination, Consideration Transferred, Other	659,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other.1	868,000
Total consideration for 55% holding	$ 60,544,000

v3.24.2.u1

Certain Transactions - Purchase Price Allocation (Details)	Jun. 30, 2024 USD ($)
Restructuring and Related Activities [Abstract]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	$ 10,342,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Assets	7,064,000
Intangible assets	21,929,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other_MB	(605,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	38,730,000
Goodwill	$ 21,814,000

v3.24.2.u1

Revenues (Details) - Schedule of disaggregation of revenues - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	$ 138,041	$ 159,751	$ 282,091	$ 309,128
Total revenues recognized in point in time [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	106,441	123,268	219,409	237,930
Total revenues recognized over time [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	31,600	36,483	62,682	71,198
Products [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	93,594	109,112	192,790	210,083
Products [Member] | Total revenues recognized in point in time [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	93,594	109,112	192,790	210,083
Services [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	44,447	50,639	89,301	99,045
Services [Member] | Total revenues recognized in point in time [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	12,847	14,156	26,619	27,847
Services [Member] | Total revenues recognized over time [Member]
Revenues (Details) - Schedule of disaggregation of revenues [Line Items]
Total Revenues	$ 31,600	$ 36,483	$ 62,682	$ 71,198

v3.24.2.u1

Revenues (Details) - Schedule of changes in deferred revenue - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule Of Changes In Deferred Revenue Abstract
Deferred revenue	$ 69,794	$ 76,265	$ 69,794	$ 76,265
Revenue Recognition, Milestone Method [Line Items]
Total net sales	138,041	159,751	282,091	309,128
Transferred at Point in Time [Member]
Revenue Recognition, Milestone Method [Line Items]
Total net sales	106,441	123,268	219,409	237,930
Transferred over Time [Member]
Revenue Recognition, Milestone Method [Line Items]
Total net sales	31,600	36,483	62,682	71,198
Products
Revenue Recognition, Milestone Method [Line Items]
Total net sales	93,594	109,112	192,790	210,083
Products | Transferred at Point in Time [Member]
Revenue Recognition, Milestone Method [Line Items]
Total net sales	93,594	109,112	192,790	210,083
Service [Member]
Revenue Recognition, Milestone Method [Line Items]
Total net sales	44,447	50,639	89,301	99,045
Service [Member] | Transferred at Point in Time [Member]
Revenue Recognition, Milestone Method [Line Items]
Total net sales	12,847	14,156	26,619	27,847
Service [Member] | Transferred over Time [Member]
Revenue Recognition, Milestone Method [Line Items]
Total net sales	$ 31,600	$ 36,483	$ 62,682	$ 71,198

v3.24.2.u1

Revenues - Narrative (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2024	Dec. 31, 2023
Revenue Recognition [Abstract]
Deferred Long-Term Liability Charges	$ 18,900,000	$ 18,900,000	$ 23,700,000
Revenue recognized	14,500,000	33,100,000
Remaining performance obligations	98,300,000	98,300,000
Expected remaining performance obligations recognized during next 12 months	68,000,000.0	68,000,000.0
Expected remaining performance obligations recognized subsequent to next 12 months and thereafter	14,700,000	14,700,000
Expected remaining performance obligations recognized remainder thereafter	15,600,000	15,600,000
Deferred sales commissions	$ 10,300,000	$ 10,300,000	$ 10,300,000

v3.24.2.u1

Inventories (Details) - Schedule of inventories - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule Of Inventories Abstract
Finished goods	$ 95,670	$ 86,908
Raw materials	9,870	9,871
Work-in-process	90,965	96,197
Inventories	$ 196,505	$ 192,976

v3.24.2.u1

Goodwill and Other Intangible Assets (Details) - Schedule of changes in the carrying amount of goodwill $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Balance at beginning	$ 100,051
Balance at ending	99,174
Goodwill
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Balance at beginning	100,051
Currency translation adjustments	(877)
Balance at ending	$ 99,174

v3.24.2.u1

Goodwill and Other Intangible Assets (Details) - Schedule of other intangible assets - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Carrying Amount, Net of Impairment	$ 552,041	$ 551,749
Accumulated Amortization	(435,580)	(423,968)
Other intangible assets, net	116,461	127,781
Developed technology [Member]
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Carrying Amount, Net of Impairment	403,035	403,180
Accumulated Amortization	(309,542)	(300,780)
Other intangible assets, net	93,493	102,400
Patents [Member]
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Carrying Amount, Net of Impairment	20,975	19,396
Accumulated Amortization	(11,041)	(10,246)
Other intangible assets, net	9,934	9,150
Trademarks and trade names [Member]
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Carrying Amount, Net of Impairment	22,161	22,286
Accumulated Amortization	(16,940)	(15,936)
Other intangible assets, net	5,221	6,350
Customer relationships [Member]
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Carrying Amount, Net of Impairment	102,634	102,520
Accumulated Amortization	(94,821)	(92,639)
Other intangible assets, net	7,813	9,881
Capitalized software development costs [Member]
Other Intangible Assets, Net (Details) - Schedule of other intangible assets [Line Items]
Carrying Amount, Net of Impairment	3,236	4,367
Accumulated Amortization	(3,236)	(4,367)
Other intangible assets, net	$ 0	$ 0

v3.24.2.u1

Goodwill and Other Intangible Assets (Details) - Narrative - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Schedule Of Changes In The Carrying Amount Of Goodwill Abstract
Amortization of intangible assets	$ 5,700,000	$ 7,100,000	$ 12,600,000	$ 13,300,000

v3.24.2.u1

Goodwill and Other Intangible Assets (Details) - Estimated Amortization Expense $ in Thousands	Jun. 30, 2024 USD ($)
Schedule Of Changes In The Carrying Amount Of Goodwill Abstract
2024	$ 11,245
2025	21,336
2026	21,247
2027	20,320
2028	16,290
2029 and thereafter	26,023
Net Book Value	$ 116,461

v3.24.2.u1

Net Loss per Share (Details) - Schedule of calculation of basic and diluted net loss per share - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Numerator:
Net loss attributable to Stratasys Ltd. for basic and diluted net loss per share	$ (25,743)	$ (38,615)	$ (51,726)	$ (60,839)
Denominator:
Weighted average shares – denominator for basic and diluted net loss per share	70,746,000	68,648,000	70,367,000	68,107,000
Earnings Per Share, Basic	$ (0.36)	$ (0.56)	$ (0.74)	$ (0.89)

v3.24.2.u1

Net Loss per Share - Narrative (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Earnings Per Share [Abstract]
Anti-dilutive shares, excluded from computation of diluted net loss per share	5,500,000	3,000,000	3,900,000	3,300,000

v3.24.2.u1

Fair Value Measurement (Details) - Schedule of financial assets and liabilities that are carried at fair value on a recurring basis - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Liabilities:
Foreign exchange forward contracts fair value	$ 1,489	$ 1,543
Accounts Payable and Accrued Liabilities, Fair Value Disclosure	6,500	6,700
Fair Value, Inputs, Level 1
Assets:
Marketable Securities	828	1,994
Level 2 [Member]
Assets:
Foreign exchange forward contracts not designated as hedging instruments	82	164
Foreign exchange forward contracts designated as hedging instruments	1,485	2,087
Liabilities:
Foreign exchange forward contracts not designated as hedging instruments	(31)	(51)
Foreign exchange forward contracts designated as hedging instruments	(47)	(657)
Foreign exchange forward contracts fair value	1,489	1,543
Level 3 [Member]
Assets:
Convertible Debt, Fair Value Disclosures	8,786	7,018
Liabilities:
Contingent consideration	(18,371)	(18,603)
Schedule Of Fair Value Measurements Are Estimated Utilizing Level3 Inputs Abstract	$ 9,585	$ 11,585

v3.24.2.u1

Fair Value Measurement (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Accounts Payable and Accrued Liabilities, Fair Value Disclosure	$ 6,500	$ 6,700

v3.24.2.u1

Derivatives and Hedging Activities (Details) - Schedule of balance sheet classification and fair values of derivative instruments € in Thousands, $ in Thousands	Jun. 30, 2024 USD ($)	Jun. 30, 2024 EUR (€)	Dec. 31, 2023 USD ($)
Derivatives, Fair Value [Line Items]
Notional amount of derivative asset	$ 82,800	€ 36,000
Fair value	1,489		$ 1,543
Notional amount	150,036		229,925
Conversion To NISMember
Derivatives, Fair Value [Line Items]
Notional amount of derivative asset	27,300
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other current assets [Member]
Derivatives, Fair Value [Line Items]
Fair value derivative asset	82		164
Notional amount of derivative asset	35,581		82,873
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses and other current liabilities [Member]
Derivatives, Fair Value [Line Items]
Fair value derivative liability	(31)		(51)
Notional amount of derivative liability	47,237		21,168
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Other current assets [Member] | Cash Flow Hedge [Member]
Derivatives, Fair Value [Line Items]
Notional amount of derivative asset			51,830
Fair value derivative asset	1,485		2,087
Notional amount of derivative asset	54,152
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses and other current liabilities [Member] | Cash Flow Hedge [Member]
Derivatives, Fair Value [Line Items]
Notional amount of derivative asset			657
Fair value derivative liability	(47)
Notional amount of derivative liability	$ 13,066		$ 74,054

v3.24.2.u1

Derivatives and Hedging Activities (Details) € in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 EUR (€)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Notional amount of derivative asset	$ 82,800		$ 82,800		€ 36,000
Unrealized Gain (Loss) on Derivatives	$ 500	$ 1,600	$ 1,800	$ 1,200

v3.24.2.u1

Equity (Details) - Schedule of stock-based compensation expense - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expenses	$ 7,346	$ 8,022	$ 15,995	$ 16,263
Cost of revenues [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expenses	1,010	999	1,962	1,931
Research and Development, Net [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expenses	2,120	1,867	4,251	3,956
Selling, General and Administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expenses	$ 4,216	$ 5,156	$ 9,782	$ 10,376

v3.24.2.u1

Equity (Details) - Schedule of stock option activity	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Schedule Of Stock Option Activity Abstract
Options outstanding, Number of Options | shares	1,360,652
Options outstanding, Weighted Average Exercise Price | $ / shares	$ 20.67
Granted, Number of Options | shares	0
Granted, Weighted Average Exercise Price | $ / shares	$ 0
Exercised, Number of Options | shares	(12,413)
Exercised, Weighted Average Exercise Price | $ / shares	$ 12.30
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period | shares	(54,569)
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | $ / shares	$ 24.30
Options outstanding, Number of Options | shares	1,293,670
Options outstanding, Weighted Average Exercise Price | $ / shares	$ 20.60
Options exercisable, Number of Options | shares	1,014,148
Options exercisable, Weighted Average Exercise Price | $ / shares	$ 21.80

v3.24.2.u1

Equity (Details) - Schedule of RSUs and PSUs activity - $ / shares	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Equity (Details) - Schedule of stock options outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	(54,569)
Restricted And Phantom Share Units Member
Equity (Details) - Schedule of stock options outstanding [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number	4,475,973	3,842,232
Granted, Number of RSUs and PSUs	1,867,931
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period	1,020,493
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period	(213,697)
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 18.83	$ 17.95
Granted, Weighted Average Grant Date Fair Value	11.77
Vested, Weighted Average Grant Date Fair Value	19.12
Forfeited, Weighted Average Grant Date Fair Value	$ 19.14

v3.24.2.u1

Equity (Details) - Schedule of accumulated other comprehensive loss - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	$ (7,079,000)	$ (12,818,000)
Other comprehensive loss before reclassifications	(751,000)	(874,000)
Amounts reclassified from accumulated other comprehensive loss	(1,303,000)	1,021,000
Other comprehensive income (loss)	(2,054,000)	147,000
Balance	(9,133,000)	(12,671,000)
Net unrealized gain (loss) on cash flow hedges [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	1,790,000	(299,000)
Other comprehensive loss before reclassifications	1,459,000	(2,708,000)
Amounts reclassified from accumulated other comprehensive loss	(1,303,000)	1,021,000
Other comprehensive income (loss)	156,000	(1,687,000)
Balance	1,946,000	(1,986,000)
Foreign currency translation adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	(8,869,000)	(12,519,000)
Other comprehensive loss before reclassifications	(2,210,000)	1,834,000
Amounts reclassified from accumulated other comprehensive loss	0	0
Other comprehensive income (loss)	(2,210,000)	1,834,000
Balance	$ (11,079,000)	$ (10,685,000)

v3.24.2.u1

Equity (Details)	6 Months Ended
	Jun. 30, 2024 USD ($)
Equity (Details) [Line Items]
Unrecognized compensation cost (in Dollars)	$ 55,700,000
Employee Stock Option [Member]
Equity (Details) [Line Items]
Weighted average period over which unrecognized compensation cost will be recognized	1 year 6 months 21 days
Unrecognized compensation cost (in Dollars)	$ 300,000

v3.24.2.u1

Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Goodwill [Line Items]
Goodwill	$ 99,174	$ 100,051
Goodwill
Goodwill [Line Items]
Goodwill	99,174	$ 100,051
Currency translation adjustments	$ (877)

---